Law Updates

Latest notifications, circulars, orders and compliance changes.

From

Department

Reset

Tip: Use date range and department to narrow down results.

Showing 6 of 10 result(s)

Clear filters

Subject

Medical Devices (Third Amendment) Rules, 2026: What Has Changed for QMS, Testing Labs and EU-Approved Devices?

Summary: The Medical Devices (Third Amendment) Rules, 2026, change a small but important part of the Medical Devices Rules, 2017. The Ministry of Health and Family Welfare has added Quality Management System (QMS) compliance to the self-certification requirements under Rules 19H and 19J, changed the heading used for government medical device testing laboratories, and added European Union countries to a specific provision under Rule 63. The QMS change is particularly relevant to manufacturers and importers of Class A non-sterile and non-measuring medical devices. The Rule 63 amendment has a different purpose. It concerns certain investigational medical devices that lack a predicate device and already have regulatory and marketing histories in specified overseas jurisdictions. So, this is not a new licensing system for the entire medical device industry. Its impact depends on the rule under which a business or product currently operates. Notification at a Glance Particular Details Issuing Ministry Ministry of Health and Family Welfare Department Department of Health and Family Welfare Rules Medical Devices (Third Amendment) Rules, 2026 Principal Rules Medical Devices Rules, 2017 Governing Law Drugs and Cosmetics Act, 1940 Provisions Changed Rules 19H, 19J, Rule 19 marginal heading and Rule 63 Main QMS Change Rules 19H, 19J, Rule 19 marginal heading and Rule 63 Rule 63 Change European Union countries added after Japan in Proviso (iv) Main Businesses Affected Relevant Class A manufacturers and importers, applicants covered by Rule 63 The notification itself is only three pages long. The important part is not its length, but where these changes sit within the existing Medical Devices Rules. Rules 19H and 19J address a specific category of Class A devices, whereas Rule 63 addresses an entirely different regulatory situation. What Are the Medical Devices (Third Amendment) Rules, 2026? The Medical Devices (Third Amendment) Rules, 2026, do not replace the Medical Devices Rules, 2017. They amend selected provisions of the existing rules. This distinction matters because a reader could otherwise look at the QMS amendment and assume that a completely new certification or licensing system has been introduced. That is not what it says. The final rules make four changes: QMS is expressly added to the self-certification requirement in Rule 19H(2)(v). The same QMS wording is added to Rule 19J (2) (v). The marginal heading of Rule 19 is changed to “Government Medical Device Testing Laboratories.” European Union countries are added to Rule 63(1), Proviso (IV). Each of these changes must be read in conjunction with the original provision. Looking only at the amendment would tell a business what words have changed, but not necessarily how those words affect its regulatory position. Why Was This Amendment Introduced? The final Gazette gives the legal amendments, but earlier proceedings of the Drugs Technical Advisory Board (DTAB) provide useful background on why some of these changes were proposed. Closing the QMS gap for certain Class A devices Chapter IIIB of the Medical Devices Rules applies to Class A non-sterile and non-measuring medical devices. Under that framework, manufacturers and importers obtain registration by submitting prescribed information through the Online System for Medical Devices rather than following the licensing framework used for other categories. During its 91st meeting, DTAB noted that Rules 19H and 19J already addressed registration and self-certification for these devices. Still, the scope of conformity with the Quality Management System was not expressly included in those clauses. The Board's discussion linked QMS with the need to ensure that medical devices meet applicable standards and essential principles relating to safety and performance. DTAB therefore agreed with the proposal to add QMS requirements to Rules 19H and 19J. The 2026 amendment puts that proposal into the rule text. Distinguishing government laboratories from private testing laboratories There was also a terminology issue around Rule 19. The Medical Devices Rules separately use the term “medical devices testing laboratory” to refer to laboratories registered to test or evaluate devices on behalf of manufacturers. DTAB considered that the Rule 19 heading should make it clearer that the laboratories covered there are government testing laboratories. Its minutes specifically record the proposal to change the heading from “Medical Device Testing Laboratories” to “Government Medical Device Testing Laboratories.” Adding the European Union to Rule 63 The EU-related change has a longer history. DTAB records show that the exclusion of the European Union from the countries listed in Rule 63 had been raised during an India-EU Sub-Commission on Trade meeting held on 6 June 2018. The Board later recommended amending Rule 63(1) to include the European Union. It now makes that addition in the final rules. From Draft Rules to the Final Amendment The Government first placed these changes before the public in draft form. Proposed amendments to Rules 19H, 19J, Rule 19 and Rule 63. The draft notification invited objections and suggestions from people likely to be affected. The consultation period was 30 days from the date on which copies of the Gazette were made available to the public. The final notification records that the Gazette copies were made available on 10 April 2026 and that the Central Government considered the objections and suggestions it received before finalising the rules. For compliance purposes, the difference is straightforward: It was a draft proposal. IT contains the final rules. Companies that reviewed the April draft should now update their internal notes and work from the final notification. When Do the Medical Devices (Third Amendment) Rules, 2026 Apply? The rules say that, unless a provision states otherwise, they come into force on the date of their final publication in the Official Gazette. There are a few dates on the document, which can be confusing. The Ministry's notification is dated 14 August 2026. The Gazette issue carrying the notification is dated 19 August 2026. Because commencement is tied to final publication rather than merely the date written below the Ministry heading, businesses should work from the final Gazette publication dated 19 August 2026. The notification does not provide a separate transition period for the four amendments. What Has Actually Changed? The easiest way to understand the amendment is to separate the four changes rather than treating them as one large reform. Provision Earlier Position Position After IT What It Means Rule 19H(2)(v) Manufacturer self-certified compliance with standards specified in the Rules QMS is now also expressly included Relevant Class A manufacturers must address QMS in the self-certification Rule 19J(2)(v) Importer self-certified compliance with standards specified in the Rules QMS is expressly added Relevant Class A importers must also address QMS Rule 19 heading “Medical Device Testing Laboratories” “Government Medical Device Testing Laboratories” Makes the government-laboratory context clearer Rule 63(1), Proviso (iv) UK, USA, Australia, Canada and Japan were listed European Union countries are added Certain EU regulatory history may now be considered under the existing proviso The first two changes affect the wording of an existing compliance declaration. The Rule 19 change mainly clarifies terminology. The Rule 63 amendment expands a country list inside an already conditional provision. Those differences should be kept in mind before deciding what action, if any, a business needs to take. QMS Is Now Expressly Included Under Rule 19H Rule 19H applies to the manufacturer of a Class A non-sterile and non-measuring medical device. Chapter IIIB states that these devices are registered via a designated online portal. Rule 19H then lists the information the manufacturer must upload. That includes manufacturing-site details, device details, classification-related declarations, and self-certification relating to safety, performance, and standards. Before IT, clause (v) required the manufacturer to self-certify compliance with the standards specified in the Rules. The new amendment inserts the words “and Quality Management System” after “standards”. That may look like a small drafting change, but it changes what the manufacturer's self-certification must cover. A manufacturer relying on Rule 19H now needs to be confident that it can support a declaration covering both the applicable standards and the QMS required under the Medical Devices Rules. This is where a proper internal quality review becomes more useful than simply updating the wording on a regulatory checklist. What Changes Under Rule 19J for Importers? Rule 19J deals with the import of Class A non-sterile and non-measuring medical devices. The importer uploads prescribed information on the Online System for Medical Devices. Under the existing rule, this includes information about the importer and manufacturing site, details of the device, an undertaking about its Class A status, self-certification against essential safety and performance principles, self-certification against applicable standards, and specified overseas establishment or free-sale evidence. IT now adds “and Quality Management System” to clause (v). For an importer, the practical issue is slightly different from that faced by an Indian manufacturer. The importer makes the declaration in India, but the overseas manufacturing site controls the manufacturing process. The importer therefore needs enough reliable information from that manufacturer to understand whether the QMS requirement being certified is actually met. This does not mean an importer should automatically start collecting every quality document held by a foreign manufacturer. It does mean that the basis for the self-certification should be clear and defensible. Businesses uncertain about how much QMS evidence is relevant to a particular registration may need a product-specific review rather than a generic checklist of documents. This is one area where a medical device regulatory consultant can help identify the applicable rule and avoid unnecessary filings or unsupported declarations. What Does “Quality Management System” Mean Under the Medical Devices Rules? QMS is not a new term introduced in 2026. The Medical Devices Rules already define the Quality Management System as the requirements for manufacturing medical devices specified in the Fifth Schedule. A QMS is, in practical terms, the organised system through which a manufacturer controls how a medical device is made and checked. It is broader than testing the finished product. Depending on the applicable requirements, it addresses matters such as documented processes, responsibilities, manufacturing controls, quality checks, records, and problem handling. That distinction explains why the Government chose to mention QMS alongside standards expressly. A product can be designed against a particular technical standard, but consistent quality also depends on how the manufacturing operation is controlled day after day. DTAB's own discussion described QMS as important for ensuring that devices meet relevant standards and essential principles of safety and performance, and referred to adherence to the Fifth Schedule. Does the Amendment Mean Every Business Needs a New QMS Certificate? No. IT does not itself create a new standalone QMS certificate or say that every Class A registrant must obtain a new ISO 13485 certificate. The actual amendment is narrower. It changes the existing self-certification requirement so that the manufacturer or importer certifies compliance with the standards and Quality Management System specified under the Medical Devices Rules. That wording should be followed as written. A company should therefore avoid two extremes. One is to ignore the QMS addition, as no new licence form has been introduced. The other is to assume that the notification automatically creates a completely new certification procedure that is not actually stated in the rule. The right compliance response begins with the device category, the applicable registration provision, and the QMS requirements relevant to the manufacturing operation. What Has Changed for Government Medical Device Testing Laboratories? Rule 19 now carries the marginal heading: “Government Medical Device Testing Laboratories.” The reason behind the wording is easier to understand when Rule 19's recent history is considered. A 2023 amendment changed the framework to recognise State Medical Devices Testing Laboratories. It allowed a State Government to establish such a laboratory or designate an eligible laboratory for specified testing and evaluation functions. At the same time, the Rules also use the expression “medical devices testing laboratory” for laboratories registered under a different provision to perform testing or evaluation on behalf of manufacturers. DTAB later observed that the headings should distinguish government testing laboratories from private medical device testing laboratories. The 2026 amendment therefore changes the heading. It does not, by itself: Create a new government laboratory, Introduce a fresh testing procedure, Change test parameters, Establish a new laboratory registration form, or Introduce a separate testing fee. For most manufacturers and importers, this is therefore a terminology and regulatory-reference issue rather than a new filing obligation. Rule 63 Now Includes European Union Countries The fourth change differs significantly from the QMS amendments. Rule 63 concerns permission to import or manufacture a medical device that has no predicate device. Under the existing rule, the authorised agent in the case of import, or the manufacturer in the case of domestic manufacture, applies to the Central Licensing Authority in Form MD-26 along with the prescribed information and fee. Where permission is granted, it is issued in Form MD-27. The rule also contains several provisos addressing situations in which clinical data requirements may be treated differently. One of those provisos covered devices approved by regulatory authorities in the: United Kingdom, United States of America, Australia, Canada, or Japan. IT inserts “European Union countries” after Japan. That is the legal change. What it does not do is give every EU-approved medical device an automatic right to enter the Indian market. What Was the Earlier Rule 63 Position? Under the pre-amendment wording, results of clinical investigation could, subject to the rule, not be required to be submitted where a regulatory authority had approved an investigational medical device in one of the listed countries. But foreign approval was only one part of the condition. The rule also required that the device have been marketed in that country for at least two years. The Central Licensing Authority had to be satisfied with its safety, performance and pharmacovigilance data. The provision further addresses whether there is evidence or a theoretical possibility of differences in behaviour and performance in the Indian population and requires a written undertaking concerning post-market clinical investigation. So even before the EU was added, the provision did not operate as a simple “approved abroad = automatically approved in India” rule. That remains true after the amendment. What Does the EU Addition Change in Practice? The main change is that qualifying regulatory history from European Union countries can now fall within this particular Rule 63 proviso. For an applicant with a device that does not have a predicate device, this may be relevant where the product already has the required approval and marketing history in an EU country. The applicant still needs to satisfy the remaining conditions. The Central Licensing Authority also continues to have a regulatory role. IT has not removed the Rule 63 permission process. This means phrases such as “EU medical devices are now exempt from Indian clinical investigation” would be too broad. A more accurate way to describe the amendment is: EU countries have been added to the overseas jurisdictions recognised under a conditional Rule 63 provision in which clinical investigation results may not be required to be submitted if the prescribed conditions are met. For companies dealing with such products, a review of medical device import compliance services may be useful before relying on the amended provision, particularly where foreign approvals, marketing history and Indian regulatory evidence need to be read together. Why Was the European Union Added? The Government's regulatory discussion on this issue dates back several years. Minutes of the 91st DTAB meeting record that the matter had been raised during the India-EU Sub-Commission on Trade held on 6 June 2018. The concern was that Rule 63 referred to the US, the UK, Australia, Canada, and Japan, but not the EU. DTAB subsequently recommended amending Rule 63(1) to include the European Union. The final 2026 amendment gives effect to that recommendation. For businesses, the important takeaway is not that Indian requirements have been removed for EU devices. The change is that EU regulatory history now receives express recognition under this provision, subject to the conditions already set out in Rule 63. Who Should Pay Close Attention to the Amendment? The amendment is not equally relevant to every company in the medical device sector. Stakeholder Main Issue to Review Indian manufacturers of Class A non-sterile and non-measuring devices QMS self-certification under Rule 19H Importers of Class A non-sterile and non-measuring devices QMS self-certification under Rule 19H Overseas manufacturers supplying such Class A products QMS information needed to support the Indian importer's position Authorised agents handling devices without predicate devices QMS information needed to support the Indian importer's position Manufacturers of devices without predicate devices QMS information needed to support the Indian importer's position Manufacturers of devices without predicate devices Updated Rule 19 terminology Regulatory affairs teams Correct applicability and updated rule references Quality teams Evidence supporting QMS compliance A manufacturer of a Class C device with no connection to Rule 63, for example, should not assume that a new Rule 19H registration requirement suddenly applies to it. The first question should always be: Which amended rule actually covers this product or activity? What Does This Mean for Class A Medical Device Manufacturers? For a manufacturer already registered under the Class A non-sterile and non-measuring route, the practical focus should be on self-certification. The company should review whether its quality system is aligned with the relevant Fifth Schedule requirements and whether its regulatory records are consistent with that position. This is not simply a paperwork exercise. When a business signs a self-certification, the value of that declaration comes from the records and controls behind it. Rule 19L also requires manufacturers and importers under this chapter to maintain relevant manufacturing or import records together with sales or distribution records and to produce specified records when requested by the licensing authorities. The amendment therefore makes it sensible to review QMS evidence alongside the existing registration record, rather than updating a single sentence in isolation. What Does This Mean for Importers? Importers have an extra layer to manage because the manufacturing site is outside India. Rule 19J places the self-certification obligation on the importer. At the same time, the underlying quality processes will generally sit with the overseas manufacturer. A sensible review may therefore cover: Whether the device is correctly treated as Class A non-sterile and non-measuring, Whether the overseas manufacturing site details match the registration record, What information supports QMS conformity Whether applicable product standards have been correctly identified, Whether free-sale or establishment documentation remains consistent with the registration, and Whether the submitted declaration can be supported by the records available to the importer. Not every importer will need the same documents. The exact evidence depends on the product, manufacturing arrangement, and regulatory record. A medical device regulatory consultant or an experienced internal regulatory team can be useful here, as the aim is not to compile the largest possible file. It is to identify what actually supports the legal declaration. Does IT Create a New License or Registration? IT does not introduce a new license category, a new registration form, or a separate application merely because QMS has been added to Rules 19H and 19J. The Class A registration route already existed. The amendment changes what is expressly covered by the self-certification within that route. Similarly: The Rule 63 permission mechanism already existed, Form MD-26 and Form MD-27 already formed part of that framework, Rule 19 already dealt with testing laboratories, and The 2026 notification does not prescribe a new standalone government testing-laboratory filing. This distinction can save companies from unnecessary compliance work. The correct response is to update the existing applicable process rather than invent a new one. Compliance Readiness Checklist for Medical Device Businesses The purpose of this exercise is not to create more documents. It is to make sure the documents already relied upon tell the same regulatory story as the amended rules. Compliance Risks Worth Avoiding Treating the Amendment as Applicable to Every Medical Device Rules 19H and 19J have a defined scope. They fall under the framework for Class A non-sterile, non-measuring devices. Applying these provisions to an unrelated device category can lead to the wrong compliance route. Updating the Declaration but Not Checking the QMS Changing the wording of a self-certification is easy. Being able to support it is the more important part. Affected manufacturers and importers should understand the evidence underpinning the QMS declaration before submitting or relying on it. Assuming ISO Certification Is Automatically the Entire Answer The 2026 amendment refers to the Quality Management System specified in the Medical Devices Rules. The Rules themselves link QMS to the Fifth Schedule. A certificate may be relevant in a particular compliance setting, but IT should not be rewritten to require every affected business to obtain a new ISO certificate. Assuming Any EU Approval Is Enough under Rule 63 The amendment adds EU countries to the list. It does not delete the other conditions. A company should therefore avoid relying solely on an EU approval certificate and instead consider factors such as marketing history, safety, performance, pharmacovigilance, and other requirements under the proviso. Confusing Rule 63 with the Regular Import Route Rule 63 deals with medical devices without a predicate device. It is not a general shortcut for every medical device being imported from Europe. Is This More of a Regulatory Clarification or an Additional Burden? It is a mixture of both, although the nature of the impact differs across the four amendments. Regulatory Benefit Possible Business Effort QMS responsibility is stated more clearly for the relevant Class A registration route Businesses may need to review the evidence supporting self-certification Government testing laboratories are more clearly distinguished from other testing laboratories Internal regulatory references may need updating EU countries are expressly brought within the specified Rule 63 proviso Applicants still need to prove that all other conditions are met Existing gaps in wording are reduced Regulatory and quality teams need to understand the amended text For Class A manufacturers and importers, the QMS addition clarifies compliance expectations. That can mean additional work where QMS records were not previously reviewed as part of the registration process. At the same time, the Government has not added an entirely separate application or licensing layer. The Rule 63 amendment is more clearly a regulatory expansion of an existing provision. It gives EU regulatory history a place within the specified proviso. However, the protection built into the rule remains: the applicant must still meet the conditions, and the Central Licensing Authority must still be satisfied. The Rule 19 heading is the least burdensome of the changes. Its main purpose is clarity. What Should Businesses Do Now? The best response is not to reopen every medical device file in the company. Start with the products that actually fall under one of the amended provisions. First, check classification. Manufacturers and importers should determine whether any product is registered as a Class A non-sterile, non-measuring medical device. Next, review the current registration record. Review the self-certification used under Rule 19H or Rule 19J, and ensure the amended QMS requirement is understood. Then look behind the declaration. Quality and regulatory teams should assess whether the available QMS records provide a reasonable basis for certification. For imports from the EU, separate ordinary imports from Rule 63 cases. The fact that a device comes from Europe does not, by itself, make the new proviso relevant. For genuine Rule 63 cases, review every condition. Country approval is only one part of the analysis. Update internal references. SOPs, regulatory trackers and compliance notes that reproduce the old wording of the affected provisions should be corrected. Keep watching official CDSCO updates. If operational guidance is issued later on implementation, affected businesses should assess whether it changes their existing processes. How Corpseed Can Help With Medical Device Regulatory Compliance A three-page amendment can still raise difficult questions when applied to an actual product. A manufacturer may know that its product is Class A but be unsure whether the non-sterile and non-measuring registration route applies. An importer may have QMS documents from an overseas manufacturer but still need to understand whether those records adequately support the Indian self-certification. A company dealing with a device without a predicate may have European approval but may not know whether the complete Rule 63 conditions are satisfied. Corpseed can support medical device businesses in areas such as: Medical device regulatory applicability assessment: Reviewing the product, classification, and business activity to identify the relevant provisions of the Medical Devices Rules. Class A medical device registration support: Assistance with the registration framework applicable to Class A non-sterile and non-measuring devices. Quality Management System compliance review: Assessing the QMS requirements relevant to Rules 19H and 19J and reviewing whether available records support the required regulatory position. CDSCO registration services: Supporting businesses with applicable CDSCO registrations , submissions and regulatory documentation. Medical device import compliance services: Reviewing the regulatory route for imported devices, overseas manufacturing information and India-specific requirements. Rule 63 regulatory assessment: Examining whether the device falls within the no-predicate-device framework and whether the amended EU provision may be relevant. Technical document review: Checking regulatory records, declarations, product information and supporting documents for consistency before submission. Medical device compliance gap assessment: Comparing existing documentation and processes against the applicable Medical Devices Rules. Overseas manufacturer and authorised-agent support: Helping organise information used for Indian medical device regulatory filings involving a foreign manufacturing site. Medical device registration and licence support: Assisting with applications, amendments or ongoing regulatory processes where the applicable law requires them. Regulatory monitoring: Tracking later CDSCO and Ministry notifications that may affect the product or regulatory route. Using a medical device regulatory consultant is most useful where there is a genuine question of applicability or documentation. The aim should be to identify the right route first and file only what the law actually calls for. Corpseed's role is to assist businesses with regulatory interpretation, documentation, and filing support. Approval, permission, registration, exemption and other regulatory decisions remain with CDSCO and the competent licensing authorities. Businesses reviewing IT, Class A registration, QMS compliance, or the revised Rule 63 position can use Corpseed's medical device compliance services to organise the regulatory review and address gaps before the next filing or regulatory interaction. Key Takeaways The Medical Devices Third Amendment Rules 2026 are targeted amendments rather than a new medical device regulatory system. The most immediate change is for manufacturers and importers of Class A non-sterile and non-measuring devices, because QMS is now expressly included in the self-certification wording under Rules 19H and 19J. The other changes should also be read carefully: IT contains the final amendment to the Medical Devices Rules, 2017. The Ministry notification is dated 14 August 2026 and appears in Gazette No. 678 dated 19 August 2026. Rules 19H and 19J now expressly include the Quality Management System alongside standards. The QMS referred to under the Rules is connected with the Fifth Schedule. The Rule 19 marginal heading is now “Government Medical Device Testing laboratories.” European Union countries have been added to Rule 63(1), Proviso (IV). EU approval alone does not automatically remove Indian regulatory requirements. The notification does not create a new general license or a new registration category. Affected companies should first check applicability and then review the records behind their existing regulatory declarations.

Subject

Drugs Rule 89 Amendment 2026: Form 29 Changes, Business Impact and Compliance

Summary: The Drugs (Twelfth Amendment) Rules, 2026, have been notified by the Ministry of Health & Family Welfare. These rules modify Rule 89 of the Drugs Rules, 1945. The rule came into force on 7 August 2026. According to the Drugs Rule 89 Amendment 2026, the manufacturing licenses for ten forms will be included in the list of acceptable manufacturing license forms for drugs produced solely for examinations or tests. Previously, Forms 25 and 28 were the only forms listed under Rule 89. These include license forms for loan purposes, Schedule X, vaccines, sera, LVP, recombinant DNA substances, blood products, and umbilical cord blood stem cells. This does not mean that Form 29 has been removed. A business may still need Form 29 if its existing manufacturing license does not cover the drug concerned. The exact words "in respect of such drugs" remain central to the rule. Manufacturers should therefore check the license form, approved products, site, and proposed activity before starting a test batch. The Regulatory Framework Drugs and Cosmetics Act, 1940 The Drugs and Cosmetics Act, 1940, is the primary law governing drug regulation in India. The notification states that the Central Government used the rule-making powers given by sections 12 and 33 of the Act. The final rules were made after consultation with the Drugs Technical Advisory Board. The Board gives technical advice to the Central and State Governments on matters arising from the administration of the Act. Drugs Rules, 1945 These procedures are explained in the Drugs Rules, 1945. Rule 89 is found in Part VIII of the said rules entitled "Manufacture for Examination, Test or Analysis." Part VIII deals with small quantities made for limited technical purposes. Rules 87 and 88 cover labels. Rule 89 decides when Form 29 is needed. Rules 90 to 93 cover its application, duration, conditions, and cancellation. Meaning of Form 29 Form 29 is a license to produce particular drugs for examination, testing, or analysis purposes. Form 29 is not a general manufacturing permit. The manufactured drugs can be used only for this particular purpose. Under Rule 90, an application for Form 29 is made in Form 30 to the State Licensing Authority. It must be made or countersigned by the head of the institution or a director of the firm or company. The stated fee is Rs. 250. Rule 91 states that Form 29 normally remains in force for three years from its date of issue unless canceled sooner. It may then be renewed for one year at a time. These are existing provisions that were not amended. Background of the Regulatory Development Earlier Position Under Rule 89 Before this amendment, a person had to obtain Form 29 for test manufacture if the person did not hold Form 25 or Form 28 in respect of that drug. Other forms for loan licenses and special products were not expressly named, creating possible uncertainty. Draft Notification and Public Consultation The draft amendment was published on 21 April 2026, and it became available on 22 April 2026. Thirty days were allotted for objections and suggestions. In the last notification, the comments were acknowledged to be considered. Final Notification The final Drugs (Twelfth Amendment) Rules, 2026, were notified on 6 August and published on 7 August 2026. They came into force on publication. The final text includes Form 28E. The earlier draft text available through the Central Drugs Standard Control Organization did not appear to include Form 28E in its operative list. This is a material point when comparing the draft with the final notification. Businesses must follow the final notified text. What Has Changed? Old and New Position Compliance area Earlier position New position from 7 August 2026 Business meaning License forms named in Rule 89 Form 25 and Form 28 Ten manufacturing license forms More license categories are expressly recognized Loan licenses Not expressly named Forms 25A, 28A, and 28DA are named Loan-licensees receive clearer treatment Schedule X categories Limited express coverage Forms 25F and 28B are named Schedule X manufacturers are expressly addressed Vaccines and specialized biological products Form 28D not named Forms 28D and 28DA are named Specialized and loan-license units are covered Blood products Form 28E not named Form 28E is included Blood-product manufacturing is expressly recognized Umbilical cord blood stem cells Form 28F not named Form 28F is included Cord blood stem-cell establishments are expressly recognized The amendment substitutes the earlier words "Form 25 or Form 28" with a longer list. The new list covers Form 25, Form 25A, Form 25F, Form 28, Form 28A, Form 28B, Form 28D, Form 28DA, Form 28E, and Form 28F. What Has Not Changed The amendment does not remove the Form 29 assessment. It expands the forms considered during that assessment. It also does not: Permit commercial sale of drugs made under Form 29, Add a new drug to an existing manufacturing license, Expand an approved manufacturing site, Replace a product permission, new-drug approval, or other approval that may apply, Change Form 30 or the stated application fee, Change the three-year duration stated in Rule 91, Remove labelling, recordkeeping, inspection, or Inspection Book duties, or Create an express transition period for pending applications. License Forms Covered by Amended Rule 89 Each form covers a different permission. These broad descriptions do not replace a check of the actual license and product endorsements. Form 25 and Form 25A Form 25 covers manufacture for sale or distribution of drugs outside Schedules C, C(1), and X. Form 25A is the related loan license, allowing use of another licensed manufacturer's facilities subject to applicable conditions. Form 25F Form 25F covers Schedule X drugs not specified in Schedules C and C(1). Its inclusion clarifies Rule 89 for this category. Form 28 and Form 28A Form 28 covers drugs in Schedules C and C(1), excluding Schedule X. Form 28A is the related loan license for eligible Schedule C and C(1) drugs. Form 28B Form 28B covers drugs specified in Schedules C, C(1), and X. Form 28D and Form 28DA Form 28D is used for manufacturing parenterals, sera, vaccines, and recombinant DNA drugs in large volumes for sale/distribution, excepting those products listed in Schedule X as per the form. Form 28DA is the loan-license version for these specialized products. Form 28E Form 28E is a license to manufacture and store blood products for sale or distribution. The final amendment includes this form. This gives blood-product manufacturers an express place in the revised Rule 89 list. The English notification does not repeat the word "Form" immediately before "28E." Its placement in the list makes the reference clear, but internal notes should quote the Gazette accurately. Form 28F Form 28F covers collection, processing, testing, storage, banking, and release of umbilical cord blood stem cells. Scope and Applicability Businesses Most Likely to Be Affected The amendment affects businesses making small quantities for examination, testing, or analysis, including: Pharmaceutical manufacturers, Loan-licensees, Schedule X drug manufacturers, Vaccine and sera manufacturers, Large volume parenteral manufacturers, Recombinant DNA product manufacturers, Blood-product manufacturers, Umbilical cord blood stem-cell establishments, Research and development units attached to licensed plants, and Regulatory, quality, production, and testing teams. The Product-Specific Test The key limit is "in respect of such drugs." Holding a listed form does not automatically remove Form 29 for every test product. The business must check the drug, site, category, dosage form, activity, and product permission. If coverage is missing, Form 29 may still be required before manufacture. No Express Blanket Exemption The amendment does not use the words "blanket exemption." It changes the license form list under the existing conditions. This is why a written review of applicability is safer than relying solely on the number printed on a license. Implementation Timeline and Norms Event Date Practical meaning Draft notification issued 21 April 2026 Proposed wording was published Draft made available to the public 22 April 2026 Thirty-day consultation period began Final notification dated 6 August 2026 The government signed the final rules Official Gazette publication 7 August 2026 Amendment came into force Separate transition period Not expressly specified Businesses should apply the revised wording from commencement The rule came into force on 7 August 2026. The notice does not provide any separate compliance period or phased implementation period. It does not clearly stipulate how the State Licensing Authority is to deal with a Form 29 application pending at the time of commencement. Pending cases require a different kind of attention, as the business should not assume the application is automatically over. Instead, they should send their license, products covered, and status of the application to the licensing authority. Why Was This Implemented? Official Position The final notice concerns the legal procedure but does not provide a lengthy statement of reasons. The notice shows that the draft was published, public opinions were sought, those opinions were considered, and the Central Government acted in consultation with the DTAB. Regulatory Analysis The purpose of the regulation could be seen from the language used. Rule 89 was earlier confined to Forms 25 and 28, while the Drugs Rules included other manufacturing license forms as well. The amendment makes the Rule 89 list similar to the format of the entire license. This could help reduce confusion among specialized manufacturers. This could also ensure consistency in decision-making between companies and authorities. But this is a practical evaluation, and not a direct commitment in the notification that each application will get easier or cheaper. Impact on Businesses Pharmaceutical and Loan-License Manufacturers The persons holding Forms 25A, 25F, 28A, 28B, or 28DA can now refer to a more clearly worded document. The forms were not explicitly mentioned in Rule 89 before 7 August 2026. The use of this new language may minimize reliance on similarity to Form 25 or 28. Loan licensees still need to verify the exact license arrangement and the facility where the activity will occur. A loan license does not erase the conditions attached to the approved manufacturing premises. Vaccine and Biological-Product Manufacturers Forms 28D and 28DA are now explicitly mentioned. This is important for companies that manufacture high-volume parenterals, sera, vaccines, and products made using recombinant DNA technology. Such companies perform development and validation activities and may require a Rule 89 evaluation, which will impact their projects. The amendment does not remove other approvals that may apply to a new drug, biological product, clinical program, or product change. Rule 89 should not be read in isolation. Blood Products and Cord Blood Stem Cells The inclusion of Forms 28E and 28F adds blood products and umbilical cord blood stem cell activity to the list. This area has its own technical and safety requirements. Companies need to ensure that any reliance on the revised rule is consistent with their license. Compliance and Quality Teams There is also a need for the regulatory, quality assurance, research, and manufacturing departments to update their internal decision trees. The current process, which relies on asking whether the firm has Form 25 or 28, is outdated. The revised procedure should record all ten forms and require a product-specific check. It should also separate the legal question under Rule 89 from other approval, labeling, testing, and record duties. How Businesses Will Achieve Compliance Step 1: Check the Purpose Confirm that the drug is made only for testing or analysis. Form 29 cannot be used for commercial sale. Step 2: Check the Existing License Check which manufacturing license the business holds. Confirm that it is one of the ten forms listed under Rule 89. Step 3: Check Drug Coverage Make sure the license covers the drug being tested. Check the product, strength, dosage form, and premises. Step 4: Check Other Approvals Check whether any product, new drug, clinical trial, or other approval is needed. The Rule 89 amendment does not remove these requirements. Step 5: Check Whether Form 29 Is Needed Form 29 will be used if the license does not include the drug. Submit an application using Form 30 when you need to use Form 29. Step 6: Follow Test-Manufacturing Rules Use the drug only for testing or analysis. Keep proper labels, records, and inspection documents. Do not sell the test batch. Step 7: Keep a Written Decision Record Record: Drug and activity License number Approved premises Other approvals checked Form 29 decision Reviewer’s name and date This note is not required in this exact format, but it can help during an inspection. Documents and Records to Review Document or record Status Purpose Existing manufacturing license Required for reliance on a listed form Confirms form, holder, and premises Product list and endorsements Required to establish drug coverage Supports the "in respect of such drugs" check Form 30 application Required where Form 29 is needed Application for the test license Form 29 license Required where Rule 89 applies Authorizes specified test manufacture Labels for test material Required under Part VIII Shows the limited purpose and identification details Quantity and recipient records Required for Form 29 licensees Tracks manufacture and supply Inspection Book Required for Form 29 licensees Allows inspectors to record observations Internal applicability note Recommended Explains why Form 29 was or was not considered necessary Businesses should not use this table as a universal checklist for applications. Exact filings may depend on the product, the State Licensing Authority, the premises, and other applicable laws. Compliance Risks and Issues to Avoid Treating the Amendment as the End of Form 29 Form 29 continues to exist. The amendment changes the circumstances in which an existing manufacturing license is considered under Rule 89. A business without suitable drug coverage may still need it. Checking Only the Form Number A listed form is only the first check. The license should relate to the drug concerned. Ignoring product endorsements, premises, or approved categories can lead to a weak compliance position. Starting Manufacture Too Early Where Form 29 is required, Rule 89 requires that it be obtained before manufacture begins. Production planning should therefore include a regulatory release point before any test batch is started. Selling Test-License Material Rule 92 restricts material prepared using Form 29 to be used only for examination, testing, or analysis. Companies need to ensure that the material does not become part of their commercial supply or sales. Ignoring Labels and Records Labelling and record-keeping responsibilities are set out in Rules 87, 88, and 92. Regardless of how small the batch may be, labelling and quantity records are important issues. Benefits for Businesses The clearest benefit is better recognition of the license system already used by the pharmaceutical sector. More manufacturing forms are expressly named in Rule 89. Loan licensees receive clearer treatment. Schedule X manufacturers are specifically addressed. Vaccine, sera, large volume parenteral, and recombinant DNA product units are included. Blood product and cord blood stem cell establishments are recognized. Internal compliance checks can use a clearer form-based starting point. Businesses may avoid unnecessary Form 29 filings where an existing listed license truly covers the drug. These are possible compliance and operational benefits. The notification does not guarantee lower costs, faster approval, or exemption in every case. Is This the Right Decision or an Additional Burden? Assessment area Why is it the right decision Possible burden or concern Broader recognition of license forms The old Rule 89 referred only to Form 25 and Form 28. The amendment recognizes additional manufacturing license forms used for loan licenses, Schedule X drugs, vaccines, biological products, blood products, and other specialized categories. Businesses must identify which license form applies to their product and activity. Alignment with the current licensing system Rule 89 now better reflects the wider structure of pharmaceutical manufacturing licenses under the Drugs Rules, 1945. Compliance teams must update old policies, checklists, and decision trees that mention only Form 25 and Form 28. Reduction in regulatory uncertainty Expressly naming more license forms can reduce doubt about whether manufacturers operating under those forms are recognized under Rule 89. The amendment does not answer every product-specific question. Different interpretations may still arise. Potential reduction in duplicate paperwork Where a business already holds an appropriate manufacturing license covering the drug, a separate test license could create repetitive paperwork without materially changing the approved premises or technical capability. This benefit applies only when the existing license is genuinely “in respect of” the drug concerned. Meaning of “in respect of such drugs” The phrase ensures that the existing license must have a real connection with the drug being manufactured for examination, testing, or analysis. This is the most important area of interpretation. A license form number alone may not prove product coverage. Product permissions and endorsements The amendment recognizes more license categories without removing existing product-level controls. This protects the regulatory system from overly broad exemptions. Companies may incorrectly confuse a manufacturing license with permission to manufacture every drug at the site. Site-specific approval Keeping the assessment tied to the licensed premises helps ensure that test manufacturing occurs at an approved facility. A business may have the correct license form but plan to conduct the activity at another unit, laboratory, or pilot facility. Dosage-form coverage Product-specific assessment helps ensure that the facility is suitable for the dosage form being manufactured. A site licensed for tablets may not necessarily be authorized to manufacture sterile injections, vaccines, or another specialized dosage form. Specialized pharmaceutical products Adding forms related to Schedule X drugs, vaccines, biological products, blood products, and cord blood stem cells makes Rule 89 more relevant to specialized manufacturers. These products are subject to greater safety, quality, storage, testing, and documentation controls. Loan-license manufacturers Express recognition of loan-license forms provides greater clarity to businesses using another licensed manufacturer’s facilities. Compliance may involve both the loan-licensee and the owner of the manufacturing facility. Responsibilities can be misunderstood. New drugs and additional approvals The amendment deals with the Rule 89 and Form 29 framework. It does not weaken separate approval requirements that may apply to new drugs. A company may wrongly treat the amended rule as permission to manufacture or test a new drug without other approvals. Commercial sale restrictions The regulatory distinction between test manufacturing and commercial manufacturing remains important. It protects patients and the market from unapproved products. Businesses must maintain strict controls to prevent test batches from entering commercial distribution. Internal compliance procedures The amendment allows businesses to create a clearer and more complete Form 29 decision process. Revising SOPs, forms, software, and training programs requires time and resources. Regulatory inspections Clearer documentation can help inspectors understand why a company relied on an existing manufacturing license instead of obtaining Form 29. A weak or undocumented interpretation may be challenged during an inspection. Impact on smaller businesses The amendment may help smaller companies holding one of the newly recognized licenses by reducing uncertainty and potentially avoiding unnecessary applications. Smaller businesses may lack an in-house legal or regulatory team to interpret the phrase “in respect of such drugs.” Different State-level practices A clearer central rule can support more consistent decisions across jurisdictions. State Licensing Authorities may initially interpret or implement the amendment differently. Implementation cost The amendment does not create a completely new license category or a broad new filing obligation. Businesses may still spend money on license reviews, SOP revisions, staff training, and professional advice. Long-term regulatory benefit Broader, clearer wording can improve consistency, reduce redundant applications, and support research, testing, and product development. Benefits may be delayed if authorities and businesses do not apply the new language consistently. Risk of treating the amendment as a blanket exemption The amendment can provide relief where an appropriate existing license already covers the drug. The greatest risk is assuming that every holder of a listed license is automatically exempt from Form 29 for every drug. The amendment should be considered more as an effective clarification rather than a new licensing requirement. This is because it enhances compliance with current licensing requirements rather than introducing a new approval process. Nevertheless, the amendment's effectiveness can only be achieved through prudent, case-by-case application. Business Opportunities Created These changes may require specialized compliance services. The probabilities exist because there is a need to review existing licenses and internal systems, and not due to any guarantees of a new market. Evaluation of license applicability for test batches Support with Form 29 and Form 30 filings where applicable Evaluation of product endorsements and authorized premises Liability/loan license compliance evaluations SOP updates for research and test manufacture Training for regulatory, quality, research, and production teams Recordkeeping and inspection-readiness support Specialized advice for vaccines, biological products, blood products, and cord blood stem cells Manufacturers may also gain from clearer planning. When the legal route is known early, research, validation, and testing work can be scheduled with fewer last-minute licensing questions. What Businesses Should Do Next Immediate Review Any internal checklist for Rule 89 that includes only Forms 25 and 28 must be updated to include all ten forms and a specific question about product coverage. Product and Site Mapping Regulatory teams need to map proposed test products against existing licenses, endorsements, approved sites, and related permissions. If anything is unclear, it needs to be resolved before scheduling the batch. Pending Applications If there was any pending Form 29 application on 7 August 2026, the applicant needs to see whether the amended rule has affected their position. The notification doesn't mention that pending applications are either automatically withdrawn or approved. Ongoing Control Businesses should make the Rule 89 review part of change control or R&D batch approval. This will help ensure that the question is checked each time a new product, site, process, or license arrangement is introduced. How Corpseed Can Help Corpseed supports pharmaceutical businesses with a clear, document-based assessment of the Drugs Rule 89 amendment 2026. The process begins with a review of the company’s actual license, products, premises, and proposed test-manufacturing activity. 1. Rule 89 Applicability Assessment Check whether amended Rule 89 applies to the proposed activity.  Determine whether the existing license covers the drug.  Identify whether Form 29 is still required.  2. Manufacturing License Review Review Forms 25, 25A, 25F, 28, 28A, 28B, 28D, 28DA, 28E, and 28F.  Examine license conditions, endorsements, and validity.  Explain how the license relates to the proposed activity.  3. Product and Premises Coverage Check Confirm whether the product or dosage form is approved.  Verify that the activity will take place at licensed premises.  Identify missing product, site, or manufacturing permissions.  4. Form 29 License Consultant Support Determine whether a Form 29 license is necessary.  Prepare the required document checklist.  Support the business throughout the licensing process.  5. Form 30 Application Assistance Help prepare the Form 30 application where required.  Review drug, premises, purpose, and applicant details.  Assist with supporting documents and authority queries.  6. Pharmaceutical Regulatory Gap Assessment Analyze deficiencies in licenses and permissions.  Review labelling and testing requirements.  Suggest effective solutions to the gaps.   7. SOP and Internal Checklist Updates Update procedures that mention only Form 25 and Form 28.  Add all license forms recognized under the amended Rule 89.  Create a product-specific Form 29 decision checklist.  8. Document Review and Inspection Readiness Review licenses, product permissions, batch records, and test documents.  Organize evidence supporting the company’s regulatory decision.  Prepare teams and records for possible inspections.  9. Ongoing CDSCO and State License Compliance Support continuing CDSCO and State Licensing Authority compliance.  Assist with license amendments, renewals, and product additions.  Monitor relevant changes and help update compliance processes. 

Department: CDSCOAuthority: CDSCO

🏷️14-08-2026

Subject

CDSCO Clarifies Rule 4 Compounding Applications: Central vs State Authority, Eligibility, Process and Business Impact

Summary: The Central Drugs Standard Control Organisation has issued an important clarification on compliance regarding applications filed under Rule 4 of the Drugs and Cosmetics (Compounding of Offences) Rules, 2025. According to the CDSCO circular dated 21 July 2026, it is also made clear that, to apply for compounding of any offence, the application must be made to the competent authority having jurisdiction over such offence. This clarification was needed because, in many cases, the Central Compounding Authority was receiving applications within the jurisdiction of the State/Union Territory Drug Control Administration. This circular directly impacts all individuals and companies engaged in the manufacture, import, dealing in, distribution, wholesale dealing, marketing, and licensing of drugs and cosmetics, as per the Drugs and Cosmetics Act, 1940. The point to note is that, simply because CDSCO is the central drug regulatory body, an application to compound the offence cannot be made to the Central Authority. First, the company in question needs to know who took the sample and which licensing authority has jurisdiction over the matter. An application filed before an authority without jurisdiction may be returned or rejected. This can increase regulatory costs, delay case closure and prolong uncertainty around licences, commercial transactions and business operations. Importantly, the July 2026 circular does not create a new compounding law. It clarifies how the existing Rule 4 filing mechanism must be used. CDSCO Circular at a Glance Particular Details Issuing authority Central Drugs Standard Control Organisation Administrative department Directorate General of Health Services, Government of India Circular date 21 July 2026 CDSCO release date 22 July 2026 Subject Clarification regarding submission of applications under Rule 4 Applicable framework Drugs and Cosmetics (Compounding of Offences) Rules, 2025 Stakeholders covered Manufacturers, importers, distributors, licence holders and other applicants Main requirement Application must be filed before the competent compounding authority having jurisdiction Central jurisdiction Sample drawn by a CDSCO Drugs Inspector or offence concerning the Central Licensing Authority State jurisdiction Sample drawn by a State/UT Drugs Inspector and offence falling under the State/UT Drugs Licensing Authority Risk of filing before the wrong authority Application may be returned or rejected, requiring refiling before the competent authority What Is Compounding of an Offence? Compounding is an administrative procedure that allows certain offences to be handled without going through the entire criminal process, upon payment of the amount set by the concerned authorities and adherence to the stipulated conditions. In practical terms, it allows an eligible company or individual to approach the designated compounding authority, disclose the facts of the case, submit the prescribed application and request that the offence be compounded. The authority may examine the application, obtain a report from the relevant licensing or reporting authority, hear the applicant and decide whether the case should be compounded. If the application is accepted, the authority specifies the compounding amount and may grant immunity from prosecution subject to conditions. Compounding should not be confused with: Automatic payment of a regulatory penalty, An out-of-court private settlement, Withdrawal of every regulatory action against the applicant, Cancellation of inspection findings, Automatic protection of a drug or cosmetic licence, or A general waiver covering all past or related violations. It is a formal statutory proceeding available only for eligible offences and only with the competent authority's permission. Is compounding available as a right? No. Compounding of offences is not an absolute right of an individual. The application form for compounding of offences explicitly mentions that compounding cannot be claimed as a right by the applicant. The authority takes into account the type of offence, the applicant's disclosures, the applicant's cooperation in the case, relevant documentation, and the regulatory authority's report. Background of the Compounding Framework The Drugs and Cosmetics Act, 1940 The Drugs and Cosmetics Act, 1940 regulates the import, manufacture, distribution and sale of drugs and cosmetics in India. It establishes requirements for quality, safety, licensing, labelling, record-keeping, and enforcement for regulated businesses. The Act works through the regulatory framework at both Central and State levels. The CDSCO and the Central Licensing Authority perform certain roles at the Central level, including those concerning important imports and products under central regulation. The State and UT Drug Control Authorities handle other roles. This division of authority is one of the main reasons why businesses must carefully determine jurisdiction before filing a compounding application. Section 32B of the Drugs and Cosmetics Act Section 32B provides the statutory basis for compounding specified offences. It permits eligible offences to be compounded either before or after the institution of prosecution, subject to the statutory restrictions and prescribed procedure. The section also provides that: Only specified offences can be considered, The Central Government, State Government or an authorised officer may undertake compounding, The compounding amount cannot exceed the applicable statutory limit, A subsequent offence is not compoundable, Court permission may be required where the accused has been committed for trial or has been convicted, and an appeal is pending, and Once an offence is validly compounded, further proceedings concerning that compounded offence are restricted in accordance with the Act. The complete statutory eligibility conditions must be examined before preparing an application. Jan Vishwas (Amendment of Provisions) Act, 2023 The Jan Vishwas (Amendment of Provisions) Act, 2023 was introduced to rationalise regulatory offences, support trust-based governance, and promote ease of doing business. Among other amendments, it expanded the provisions referenced in Section 32B of the Drugs and Cosmetics Act. The relevant amendments became effective on 31 December 2024. The objective was not to weaken drug-quality regulation. It was to create a structured method for resolving eligible regulatory contraventions while allowing serious public-health violations to continue under the stricter prosecution framework. Drugs and Cosmetics (Compounding of Offences) Rules, 2025 The Ministry of Health and Family Welfare notified the Drugs and Cosmetics (Compounding of Offences) Rules, 2025 through G.S.R. 259(E) dated 24 April 2025. The Rules prescribe: Appointment of compounding authorities, Form and manner of application, Information and documents to be submitted, Procedure for obtaining the reporting authority's comments, Decision-making process, Payment of the compounding amount, Grant of immunity from prosecution, and Withdrawal of immunity in specified circumstances. Appointment of the Central Compounding Authority The Central Government appointed the Additional Director General of Health Services, who deals with CDSCO matters, as the Central Compounding Authority. The appointment authorises the officer to exercise the Central Government's powers and functions in relation to the compounding of eligible offences.  Legal and Regulatory Timeline Date Regulatory development Business significance 11 August 2023 Jan Vishwas Act received presidential assent Introduced a wider decriminalisation and trust-based compliance framework 31 December 2024 Relevant Drugs and Cosmetics Act amendments became effective Expanded the statutory compounding framework 24 April 2025 G.S.R. 259(E) notified Compounding of Offences Rules became operational 1 August 2025 S.O. 3551(E) issued Central Compounding Authority was appointed 2025–2026 CDSCO issued guidance, procedural material and FAQs Application requirements and regulatory process were explained 21 July 2026 CDSCO jurisdiction clarification issued Correct Central-versus-State filing position was clarified 22 July 2026 Circular published on the CDSCO website Clarification became publicly available to regulated stakeholders Why Did CDSCO Issue the 2026 Clarification? Applications were being filed before the wrong authority CDSCO observed that applications were being submitted to the Central Compounding Authority even when the sample had been drawn by a State or UT Drugs Inspector and the alleged offence fell under the jurisdiction of the State or UT Drugs Licensing Authority. Such applications create a jurisdictional problem. An authority must have legal competence over the alleged offence before it can process and decide the request. India follows a dual regulatory structure. Drug and cosmetic regulation in India is divided between Central and State authorities. A company may hold different licences for manufacturing, importing, selling or distributing regulated products, with different authorities controlling different parts of the business. A single company may therefore have: State manufacturing licences, Central import registrations, Medical-device permissions, Cosmetic import registrations, Wholesale or sale licences, and Multiple facilities operating across States. This regulatory structure makes it unsafe to select the compounding authority only based on the applicant's registered office or corporate location. Incorrect filing causes delay and additional cost. When an application is submitted to the wrong authority, it may have to be returned, rejected, or resubmitted. The business may then face: Duplicate professional and documentation expenses, Additional regulatory communication, Duplicate internal authorizations, Extended resolution times for cases, Uncertainty regarding prosecution, and Increased pharmaceutical legal compliance costs. For companies facing regulatory due diligence, investment, licence renewal or a business acquisition, an unresolved enforcement proceeding can also become a significant commercial concern. Uniform implementation was required. The circular creates a common principle for applicants and regulators: determine the authority connected with the sample, alleged offence and licensing jurisdiction before submitting the Rule 4 application. What Has Changed? The circular clarifies the filing forum for Rule 4 applications. The following position must now be followed clearly: A State or UT matter should be filed before the concerned State or UT Compounding Authority, A matter arising from sampling by a CDSCO Drugs Inspector should be filed before the Central Compounding Authority, A matter falling under the Central Licensing Authority should be filed before the Central Compounding Authority, and An application filed before an authority without jurisdiction is liable to be returned or rejected. The clarification places greater responsibility on applicants and their CDSCO compliance consultants to perform a jurisdiction assessment before filing. What Has Not Changed? The circular does not: Introduce a new compounding law, Replace the 2025 Rules, Create a new prescribed application form, Expand the statutory list of compoundable offences, Make every drug, cosmetic or medical-device violation compoundable, Establish a compounding amount that is universally applied, Ensure acceptance of the application, Offer automatic exemption from prosecution, Discontinue the need for honest disclosure, End the involvement of the reporting authority, Establish a new process of appeal, Automatic closure of other proceedings, or Automatic protection of the licence from suspension or cancellation proceedings. This is an important difference to make. The 2026 circular is a jurisdictional compliance notice, not a new compounding scheme. Who Is Affected? Drug manufacturers The companies under inspection, test report, show cause notice, or investigation for prosecution shall ascertain whether a State Drugs Inspector or a CDSCO officer initiated the case. Pharmaceutical importers Issues related to import tend to be Central in nature. Nevertheless, firms should investigate whether the licence, officer, breach, and enforcing authority have Central jurisdiction. Cosmetic manufacturers and importers Firms in the cosmetic sector shall determine whether the violation issue falls under State or Central jurisdiction. Medical-device and IVD businesses Medical devices notified as drugs may fall within the wider Drugs and Cosmetics regulatory framework. However, eligibility for compounding and the appropriate authority must be assessed on a case-by-case basis, based on the specific offence and licensing facts. Distributors, stockists and wholesalers Distributors and wholesalers may face allegations relating to storage, sale, records, disclosure of the product source or distribution of non-compliant products. The relevant State or Central authority will depend on the facts of the proceeding. Marketing companies and licence holders Marketing authorisation holders and businesses that market products manufactured by third parties must review whether they are separately named or implicated in the case. Directors and responsible officers Section 32B refers to eligible offences committed by companies or their officers. Separate applications may be required for different persons or entities, depending on how the proceeding was initiated. Which Offences Can Be Considered for Compounding? Section 32B refers to specified provisions of the Drugs and Cosmetics Act. Their broad nature is set out below, but actual eligibility must be determined from the current statutory language, charge and facts. Legal provision Broad subject Important eligibility consideration Section 13(1)(b) Certain prohibited import contraventions not falling within the more serious category under Section 13(1)(a) Generally connected with Central import jurisdiction, but exact facts must be verified Section 27(d) Drug-related contraventions not covered by the more serious categories in Sections 27(a), 27(b) or 27(c) Exact charge and statutory conditions require legal examination Section 27A(ii) Certain cosmetic contraventions other than the more serious spurious or adulterated cosmetic category Central or State jurisdiction depends on licensing and enforcement facts Section 28 Failure to disclose specified manufacturer or source particulars Authority depends on the inspector and underlying regulatory proceeding Section 28A Failure to maintain prescribed records or furnish required information without reasonable cause Licensing and inspection jurisdiction must be examined Just because a number exists in Section 32B does not imply that all cases filed under this section can be compounded. All statutory requirements need to be satisfied by the applicant. Statutory limitations A business needs to know whether: The specific offence falls within Section 32B, Compounding of such offences is possible through the statutory punishment scheme, It is a first-time offence, There is an issue of conviction or a subsequent offence, Prosecution of the offence has begun, The accused has been committed for trial, Conviction has taken place, and an appeal is pending, Permission from the court is needed, There have been full and frank disclosures on the part of the applicant, and Other proceedings exist under another statute. Serious offences involving spurious, adulterated or harmful products should never be assumed to be compoundable without a detailed pharmaceutical regulatory and legal assessment. Rule 4 Explained: Form and Manner of Application Rule 4 governs how an application for compounding must be made. When can the application be submitted? An application may be made either before or after the institution of prosecution. However, the stage of the case matters. If the accused has already been committed for trial, or has been convicted and an appeal is pending, court permission may be necessary under Section 32B. Who can apply? A company or individual involved in the manufacture, import, sale, distribution or another regulated activity may apply in respect of an eligible offence. Where multiple entities or individuals are involved, each applicant may need to submit an individual application. A company should not assume that its application automatically covers its directors, responsible officers, marketers or distributors. Which form must be used? The application must be submitted in the prescribed form appended to the Rules, along with relevant supporting documents. What must the applicant declare? The applicant must: Agree to pay the amount determined by the compounding authority, Acknowledge that compounding cannot be demanded as a right, Confirm that the information provided is true, Confirm that no material fact has been suppressed, Verify the authenticity of accompanying documents, and Establish the signatory's authority and competence to submit the application. How to Determine the Correct Compounding Authority Correct jurisdiction is now the most important pre-filing step. Step 1: Identify who drew the sample Review the sampling documents and establish whether the sample was drawn by: A Drugs Inspector appointed by a State or UT Government, or A CDSCO Drugs Inspector. The circular specifically links the competent authority to the authority that drew the sample. Step 2: Identification of Licensing Authority The applicant should find out whether the licence and regulated activities related to the alleged offence are governed by: State/UT Drugs Licensing Authority or Central Licensing Authority. Step 3: Identification of Subject Matter of Alleged Offence The applicant should consider whether the subject matter of the alleged offence relates to: Manufacture, Import, Sale/Distribution, Product Quality, Labeling, Disclosure of the manufacturer or source, Licence conditions, or Another regulated activity. Step 4: Review the enforcement documents The following documents can help establish jurisdiction: Sample-drawing form, Inspection report, Test or analysis report, Show-cause notice, Seizure memo, Complaint or charge sheet, Manufacturing licence, Import licence, Registration certificate, Correspondence with CDSCO or the State authority, and Details of the officer who initiated the proceeding. Step 5: Verify the designated authority Businesses should confirm that the relevant Central or State compounding authority has been appointed and obtain the latest filing instructions. If a State or UT process is unclear, the applicant should seek a written or professional assessment of jurisdiction. It should not automatically redirect the matter to the Central Authority. Central vs State Jurisdiction Matrix Regulatory situation Competent authority Sample drawn by a State/UT Drugs Inspector and offence falls under State/UT Licensing Authority Concerned State/UT Compounding Authority Sample drawn by a CDSCO Drugs Inspector Central Compounding Authority Alleged offence concerns a Central Licensing Authority matter Central Compounding Authority State officer drew the sample, and the matter is entirely State-licensed State/UT Compounding Authority Case involves Central and State licences or multiple inspecting authorities Detailed jurisdiction assessment required before filing Identity of the sample-drawing officer is unclear Review original sampling, inspection and enforcement records Application has already been filed before an authority without jurisdiction It may be returned or rejected, the applicant may have to refile Applicant’s head office is in one State but offence occurred elsewhere Jurisdiction should be based on the offence, inspector and licensing authority, not merely the head-office location Application has already been filed before an authority without jurisdiction. It may be returned or rejected; the applicant may have to refile     Effective Date and Implementation Requirements The Compounding of Offences Rules were promulgated on 24 April 2025. The clarifications regarding the jurisdiction were released on 21 July 2026. As the circular provides no future implementation date, firms planning to file new applications must strictly abide by the jurisdictional stance as clarified immediately. Companies with applications already pending before an authority should review whether the chosen authority has jurisdiction. Where an application appears to have been filed incorrectly, the company should obtain professional advice before withdrawing, amending or refiling it. Documents Required for a Rule 4 Compounding Application The official CDSCO guidance contains the application checklist and the administrative process flow. Document category Documents and information Applicant information Name, registered address, communication address and contact details Corporate authorisation Board resolution, power of attorney or authorisation of the signatory Product details Product name, composition, manufacturer, importer and marketer information Regulatory permissions Manufacturing licence, import licence, registration certificate and applicable approvals Import documentation Import Export Code and relevant import records, where applicable Quality documentation Manufacturer’s Certificate of Analysis or report from an NABL-accredited laboratory, where relevant Sampling documents Applicable sample-drawing forms, including Form 17, COS-10 or MD-36 Test reports Applicable reports such as Form 13, Form 2, COS-14, COS-21, MD-31 or MD-32 Enforcement documents Inspection report, show-cause notice, seizure memo, charge sheet or complaint Offence particulars Provisions allegedly contravened, date, location and brief facts Case status Whether prosecution is contemplated, instituted, at trial or under appeal Previous proceedings Details of earlier offences, convictions or regulatory proceedings Other laws Details of proceedings concerning the same conduct under any other law Applicant’s declaration Agreement to pay and acknowledgement that compounding is not a legal right Verification Confirmation of truthfulness, completeness and non-suppression of facts Step-by-Step Compliance Process 1. Examine the alleged offence Identify the exact section invoked in the show-cause notice, complaint, test report, or prosecution document. Do not describe the matter as compoundable until the current statutory provision and Section 32B conditions have been reviewed. 2. Determine first-offence status Determine whether the company or the concerned officer was previously convicted of the same offence or any other relevant offence. The offence is not compoundable as per Section 32B. 3. Find out at what stage the proceeding is at Ascertain if the proceeding is at: The stage of filing of prosecution, A complaint has been lodged, Committed to trial, A trial is ongoing, or an appeal is pending. This determines whether additional court permission may be necessary. 4. Conduct a jurisdiction assessment Identify: Who selected the sample, Who served the notice, By which body was the licence issued, Where the alleged offence was committed, Is it a Central or State issue, and Which compounding authority is legally empowered to do so. 5. Prepare the prescribed form Complete every applicable field. Where a field is not applicable, clearly mark it as not applicable instead of leaving it unexplained. 6. Compile supporting documents It is required to gather and organise all documents which include: Licenses, Approvals for products, Laboratory papers, Sampling papers, Inspection papers, Show-cause notices, Legal papers, and Authorisations by the corporation. 7. Prepare the factual statement The factual submission should explain: What happened, When and where it happened, The applicant's role, The alleged violation, The present status of proceedings, Corrective action taken, Preventive measures implemented, and Why the application satisfies the statutory conditions. The statement should be transparent and consistent with every document already submitted to the regulator or court. 8. Submit before the competent authority Follow the latest filing mode prescribed by the concerned Central or State authority. The filing instructions applicable to the Central Compounding Authority should not automatically be used for a State application. 9. Respond to regulatory queries The authority may request explanations, documents or additional information. Responses should be accurate, complete and filed within the allowed period. 10. Prepare for the hearing If a hearing is scheduled, the applicant should prepare: A concise chronology, Legal eligibility submissions, Technical and quality explanations, Corrective-action evidence, Licence and inspection records, and Responses to the reporting authority's observations. 11. Comply with the order If the application is allowed, the applicant must pay the specified amount within the prescribed time and furnish proof of payment. 12. Monitor immunity conditions The applicant should maintain a written record of every condition and track continuing compliance. What Happens After Filing? Once an application is received, the compounding authority seeks a report from the reporting authority having jurisdiction over the alleged offence. The reporting authority is generally the relevant licensing authority, the Central Licensing Authority, or the Central Licence Approving Authority connected with the place where the offence was committed or allegedly committed. After reviewing the application and report, the compounding authority may: Allow the application, Specify the compounding amount, Grant immunity subject to conditions, or Reject the application. Before rejecting an application, the applicant must be given a hearing, and the grounds for rejection must be recorded. Every order must be communicated to the applicant. Procedural Timelines Stage Responsible person or authority Timeline Submission of application Applicant Before or after institution of prosecution Calling for factual report Compounding Authority After receiving the application Submission of report Reporting Authority Generally within one month, subject to permitted extension Internal request to the relevant CDSCO office in a Central case Reporting Authority CDSCO guidance describes an internal five-day step Internal report by the concerned zonal, sub-zonal or port office Concerned CDSCO office CDSCO guidance describes an internal ten-day step Opportunity of hearing Compounding Authority Before rejection Payment of compounding amount Applicant Within 30 days of receiving the order Submission of payment proof Applicant Within the prescribed payment period Continuing compliance Applicant Throughout the period of any conditions imposed The compounding authority may extend the one-month reporting period. Businesses should therefore treat it as a statutory procedural benchmark, not a guaranteed final-disposal date. Grounds for Return, Rejection or Delay A Rule 4 application may face difficulty because of: Filing before an authority without jurisdiction, Incorrect identification of the sample-drawing inspector, Failure to establish statutory eligibility, Incomplete prescribed form, Missing licences or product approvals, Inconsistent dates or factual submissions, Failure to disclose previous proceedings, Missing prosecution or court documents, Absence of proper corporate authorisation, Joint filing where individual applications are required, Suppression of material information, False or misleading evidence, Failure to answer regulatory queries, Lack of supporting corrective-action records, or Failure to obtain court permission where required. A jurisdictional return should be distinguished from a rejection on the merits. If an application is returned because it was submitted to the wrong authority, that does not necessarily mean the underlying offence is ineligible. However, the applicant must still correct the filing and independently establish eligibility before the proper authority. Compounding Amount and Payment Obligations The compounding authority determines the amount after considering the application, case facts, and reporting authority's comments. Businesses should not assume there is a single standard CDSCO compounding fee applicable to every case. The amount depends on the legal provision and facts, subject to the statutory ceiling. Once an order allowing compounding is received, the applicant must generally: Pay the specified amount within 30 days, Credit the amount as directed, Preserve the payment record, and Furnish proof to the compounding authority. The amount is generally non-refundable. The Rules recognise a limited exception where the court rejects the grant of immunity. Failure to pay within the required period can result in withdrawal of immunity and continuation of prosecution. Immunity from Prosecution The compounding authority may grant immunity when satisfied that the applicant has: Cooperated during the proceedings, Made a full and true disclosure, Submitted the required information, and Complied with the conditions of the compounding order. Immunity is case-specific. It does not necessarily protect the applicant from: Unrelated offences, Proceedings under another law, Future contraventions, Separate licence suspension or cancellation, Product recall or corrective action, Civil or contractual claims, or Action arising from information that was concealed. Withdrawal of immunity Immunity may be withdrawn where the applicant: Fails to pay the compounding amount, Fails to comply with an imposed condition, Conceals a material fact, Gives false evidence, or Makes an incomplete or misleading disclosure. Once immunity is withdrawn, the applicant may be prosecuted as if the immunity had never been granted. This makes document accuracy and legal review critical. A poorly prepared application can create greater risk if it contains inconsistent statements or incomplete disclosures. Impact on Pharmaceutical, Cosmetic and Medical-Device Businesses Business area Compliance impact Regulatory strategy Jurisdiction assessment becomes a mandatory practical pre-filing exercise. Application cost Correct filing can prevent duplicate professional and documentation expenses. Case timelines Wrong filing can result in return, rejection, and refiling delays. Legal exposure Compounding remains discretionary and subject to statutory eligibility. Licence management Separate licensing proceedings may continue despite compounding. Documentation Sampling, inspection, testing and prosecution records must be traceable Management time Legal, regulatory, quality and senior-management teams must coordinate Transaction readiness Pending proceedings may affect investor, lender or acquisition due diligence. Business reputation Transparent and timely resolution may demonstrate responsible compliance conduct. Governance Directors and responsible officers need accurate visibility over pending regulatory cases. Financial and Commercial Consequences of Incorrect Filing The cost of filing before the wrong authority is not limited to the need for a fresh set of documents. Businesses may incur: Additional legal and professional fees, Further legal and professional fees, Re-filing costs for duplicate compounding application, Costs for regulatory consultants, Notarization, attestation, and authorization costs, Time of senior management, Technical evaluation of the application by quality and regulatory departments, Hearing costs and travel, Delay in conclusion of prosecution case, Lengthy period for disclosing information in the due diligence process of investment, and Reputation risk with regulators and investors. A timely jurisdiction assessment by a qualified pharma regulatory consultant in India may therefore reduce the total cost of the proceeding. How Businesses Can Achieve Compliance Immediate compliance actions Companies with pending cases involving regulatory authorities should: Examine all ongoing inspection findings, Identify all show cause notices that have been issued, Determine the section that deals with the alleged offence under Section 32B, Find out whether the case is a first offence, Identify the sampler, Determine which authority issued the license in question, Determine whether it is a matter for Central or State authorities, Determine the designated compounding authority, Identify testing and sampling records, Review the form prescribed, Establish where the prosecution is at, Seek legal opinion on court permission (if required), and Create a consistent application. Long-term compliance controls Businesses should establish: Regulatory case file registry, License to authority map, Jurisdiction matrix for each location, Sample and inspection documents, Prosecution status monitoring, Previous conviction declaration process, Pre-filing legal assessment, Records of corrective and preventative actions, Hearing response process, Conditions for payment and immunity, and Drug license and regulation compliance audits. Common Mistakes Businesses Must Avoid Treating every offence as compoundable Only specified offences can be considered. A legal eligibility review must come before application preparation. Filing every case before CDSCO CDSCO is the national regulatory organisation, but the Central Compounding Authority does not automatically have jurisdiction over State matters. Relying on the company's registered office The location of the head office is not the sole deciding factor. The inspector, offence, licence and regulatory subject matter must be examined. Ignoring the sample-drawing documents The circular gives significant importance to the authority that drew the sample. Confusing the reporting authority with the compounding authority The reporting authority provides the factual regulatory report. The compounding authority decides the application. Previous proceedings suppression Failure to disclose previous offences, prosecutions, or regulatory proceedings will affect eligibility and immunity. Inconsistency in facts used There should be consistency in the facts provided in the Rule 4 application, show-cause responses, licensing applications, lab reports, and pleadings. Thinking that payments settle all matters Payment will not suffice. Evidence must be furnished, compliance undertaken, and separate regulatory proceedings might still be needed. Missing the payment deadline Failure to pay within 30 days may result in the withdrawal of immunity. Benefits for Businesses The compounding process can provide substantial benefits in certain cases: Resolving the issue faster than through lengthy prosecution, Lowering costs incurred on litigation, Lessening the management burden, Ensuring more certainty over the ongoing proceeding, Chance to exhibit remediation measures, Enhancing cooperation with regulators, Improving preparation for due diligence with respect to regulation, Eliminating disruption arising from past technical offenses, Formal resolution of the compounded offense, and Optimization of judicial/regulatory resources. These benefits are subject to approval. No applicant should market or treat compounding as guaranteed immunity. Is the Clarification a Right Decision or an Additional Burden? The circular is broadly a positive administrative clarification because it addresses a genuine filing problem. It can reduce misdirected applications and help Central and State authorities process cases within their respective jurisdictions. However, it also requires businesses to undertake more careful due diligence before filing. Positive outcome Practical concern Clarifies the appropriate filing authority Applicants must perform a detailed jurisdiction assessment. Reduces misdirected applications Mixed Central-State cases may remain complex. Supports faster case processing State-level procedures may not be identical. Promotes uniform regulatory implementation Incorrect classification may still result in a return or rejection. Supports ease of doing business Professional legal and regulatory assistance may be required. Creates a structured alternative for eligible offences Compounding remains discretionary Encourages corrective compliance Immunity may be withdrawn for non-compliance The clarification should not be viewed as a new burden in itself. The underlying responsibility to file before the competent authority already existed. The circular makes that responsibility explicit and warns applicants about the consequences of incorrect filing. From a policy perspective, it is the right decision because it improves administrative clarity without diluting enforcement against serious violations. Business Opportunities Created The clarification is likely to increase demand for specialised regulatory and compliance support. Regulatory jurisdiction assessment Pharmaceutical, cosmetic, and medical-device businesses will need professional assistance to determine whether their matters fall under Central or State jurisdiction. Rule 4 application preparation Demand may grow for compounding application filing services, document review, and structured factual submissions. Pharmaceutical compliance audits Organizations could carry out preventive audits to detect: Gaps in licences, Documentation failures, Labelling problems, Risk of inspection, Quality problems documentation, and Compoundable past cases. Regulatory case-management services Multi-State manufacturers and distributors may require centralised monitoring of notices, hearings, prosecutions, payment deadlines and immunity conditions. Corrective and preventive action support Consultants in quality and regulation can help organizations establish appropriate corrective actions to improve their application and prevent future violations. Regulatory compliance technology The circular creates demand for digital tools that track: Licenses, Inspecting bodies, Samples of documents, Regulatory cases, Judicial proceedings, Application process, and Deadline for payments. Transactional regulatory due diligence Investors, acquirers and lenders may seek specialised pharmaceutical regulatory due diligence to assess whether pending violations are eligible for compounding and whether they could affect a business's value. How Can Corpseed Help? Preparing a Rule 4 application requires more than completing a form. The applicant must establish eligibility, identify the correct authority, organise technical records and maintain consistency across regulatory and legal documents. Corpseed can support pharmaceutical, cosmetic and medical-device businesses through a structured compliance approach. Preliminary eligibility assessment Corpseed can assist with: Reviewing the alleged offence, Identification of relevant statute, Verification of applicability of Section 32B, Assessment of first-time offence, Assessment of the stage of prosecution, and Identification of issues needing legal expertise/court approval. Central-versus-State jurisdiction assessment Our regulatory-support process can help businesses: Identify the sample drawing inspector, Evaluate the sample and inspection papers, Match the license to its issuing authority, Determine whether the matter falls under Central or State control, and Identify the appropriate compounding authority. This service can reduce the risk of an application being returned or rejected for want of jurisdiction. Documentation and application support Corpseed can provide support in: Rule 4 documents checklist, Check of the application form, Corporate authorization documents, License and registration documentation, Samples and testing documentation, Show cause and prosecution documents, Chronology preparation, Records of corrective actions, and Document indexing and organization. Filing and regulatory coordination Subject to the applicable procedure and professional scope, Corpseed can assist with: Coordinate filing before the appropriate authority, Regulatory correspondence tracking, Document requests management, Preparing structured factual responses, Coordinating technical and legal inputs, and Monitoring the progress of the application. Hearing preparation Where a personal hearing is required, Corpseed can help organise: Case chronology, Licence history, Technical explanations, Corrective and preventive action, Supporting evidence, and Responses to regulatory observations. Legal opinions and representation before courts or authorities should be undertaken through appropriately qualified legal professionals where required. Post-order compliance Corpseed can support businesses in: Tracking the payment due within 30 days, Maintaining the payment history, Submitting the payment proof, Maintaining the immunity conditions, Ensure ongoing compliance, and Make a regulatory closure document. Preventive pharmaceutical regulatory compliance services Apart from the application process, Corpseed can provide help in: Drug license compliance services, CDSCO regulatory advisory, Cosmetic compliance services, Medical device regulatory compliance, Documentation audit, License mapping, Labelling and record audit, and Compliance SOPs. Need assistance with a CDSCO Rule 4 compounding application? Get free consultation from Corpseed. We can help assess eligibility, identify the competent authority, organise supporting documents and coordinate the compliance process for pharmaceutical, cosmetic and medical-device businesses.

Department: CDSCOAuthority: CDSCO

🏷️06-08-2026

Subject

India Bans Multiple Irrational Fixed Dose Combination Drugs: Key Compliance Updates for the Pharmaceutical Industry

Summary: On 11th June 2026, the Ministry of Health and Family Welfare banned the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs across India. This fixed dose combination drug ban 2026 was issued through 16 separate notifications under Section 26A of the Drugs and Cosmetics Act, 1940, and published in the Gazette of India on 15th June 2026. If your business produces, markets, imports, or distributes any medicine in India, then this news update affects you. A prohibition order is not issued regularly. This means that the production, sale, and distribution of such combinations after the date of issuance of the notice becomes illegal. This article aims to provide simple information about the changes, the government's rationale for the decision, the combination involved, and the actions to be taken by pharma manufacturers, formulators, distributors, and retailers. The guidance becomes more complex when reformulation, stock reduction, or other regulatory issues are involved; therefore, it is necessary to consult a professional at Corpseed in such cases. Key Highlights The Central Government has prohibited the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs for human use, with immediate effect. The ban was issued through notifications S.O. 3068(E) to S.O. 3083(E), dated 11th June 2026, published in the Gazette of India on 15th June 2026. The legal basis is Section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), which empowers the Central Government to prohibit a drug when it is satisfied that its use poses a risk to human beings and safer alternatives exist. The banned list includes well-known combinations involving Amoxicillin, Cefadroxyl, Cefuroxime, Dicyclomine, Paracetamol, Gliclazide, as well as several Aloe Vera- and herbal-based fixed-dose combinations. Every combination was first flagged by an Expert Committee in 2021, which found them "irrational" for lacking supporting scientific and peer-reviewed evidence. The Drugs Technical Advisory Board (DTAB) examined the Expert Committee's findings and, in principle, agreed with the recommendation. A Sub-Committee of DTAB was formed to examine each combination in detail and allowed manufacturers and stakeholders to submit data through public notices. The Sub-Committee submitted its final report on 28th December 2024, recommending prohibition in the larger public interest. The order takes effect immediately from the date of notification there is no transition or sell-through period mentioned in the notifications. Businesses currently manufacturing, marketing, or holding stock of any of these 16 combinations must cease operations related to these combinations and review their regulatory position without delay. The Regulatory Framework Applicable Law These notifications are made under Section 26A of the Drugs and Cosmetics Act, 1940. Section 26A grants the Central Government the authority to prohibit the manufacture, sale, or distribution of any drug if it believes the drug is likely to be hazardous to humans, there are safer alternatives available, or it is not therapeutic. What Is a "Fixed Dose Combination" (FDC)? A fixed-dose combination is a single pharmaceutical product that contains two or more active ingredients in a fixed dose ratio. FDCs are common because they can improve patient compliance (fewer pills to take). Still, if the ingredients lack sound scientific justification for combination, they can pose unnecessary risks without added therapeutic benefit. This is precisely the concern raised across all 16 notifications. Scope These prohibitions apply nationwide and cover manufacture, sale, and distribution for human use. There is no exemption carved out in the notifications for existing stock, export-only production, or specific states. What Has Changed: The Full List of Banned FDCs Each of the 16 notifications follows the same regulatory process but applies to a different drug combination. Here is the complete list with their notification numbers: S.O. Notification Fixed Dose Combination S.O. 3068(E) Acetyl Salicylic Acid + Ethoheptazine S.O. 3069(E) Aloe vera + Jojoba oil + Wheat germ oil + Tea tree oil S.O. 3070(E) Amoxicillin + Serratiopeptidase + Lactobacillus Sporogenes S.O. 3071(E) Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide S.O. 3072(E) Amoxicillin + Serratiopeptidase S.O. 3073(E) Aloe Extract + Allantoin + Alphatocopherol Acetate + D-Penthenol + Vitamin A S.O. 3074(E) Aloe Extract + Vitamin E + Dimethicone + Glycerine S.O. 3075(E) Aloe Vera + Jojoba Oil + Vitamin E S.O. 3076(E) Aloe vera + Orange oil S.O. 3077(E) Aloe vera + Vitamin E + Herbal S.O. 3078(E) Dicyclomine + Paracetamol + Clidinium Bromide S.O. 3079(E) Paracetamol + Lignocaine S.O. 3080(E) Gliclazide + Chromium Picolinate S.O. 3081(E) Amoxicillin + Cloxacillin + Lactic acid bacillus + Serratiopeptidase S.O. 3082(E) Cefadroxyl + Probenecid S.O. 3083(E) Cefuroxime + Serratiopeptidase Previous Position vs New Position Aspect Before June 2026 After June 2026 Legal status of these 16 FDCs Legally manufactured, marketed and sold, subject to existing drug licences Manufacture, sale, and distribution prohibited for human use Basis for review Combinations flagged as "irrational" by Expert Committee (2021) under evaluation Formal prohibition following Sub-Committee report (Dec 2024) and DTAB recommendation Manufacturer/stakeholder input Opportunity given through public notices during Sub-Committee review Review concluded; prohibition already notified Effective date N/A Immediate effect from date of notification (11th June 2026) Common Reasons Cited Across the Notifications While each combination has its own specific finding, a few recurring reasons appear across the 16 notifications: No sound clinical or pharmacodynamic justification for combining certain active ingredients (for example, antibiotic combinations with enzyme preparations like Serrati peptidase, where the committee found no solid clinical evidence supporting concurrent use). Lack of peer-reviewed scientific evidence supporting the rationality of the combination. Deviation from standard treatment guidelines, both national and international (as seen in the Gliclazide + Chromium Picolinate combination, where standard Type 2 Diabetes treatment guidelines do not recommend Chromium Picolinate). Undefined or uncharacterized products, particularly among several Aloe vera and herbal-based topical combinations, where the committee noted the product itself was not well defined. Absence of pharmacokinetic data to justify dose combinations, as seen in the Cefadroxyl + Probenecid notification. Risk exceeding benefit in the larger public interest, even where individual ingredients may be safe on their own. Implementation Timeline / Norms Effective Date All 16 notifications state that the prohibition applies "with immediate effect" from the date of the notification, i.e., 11th June 2026. No Stated Transition Period Unlike some regulatory changes that allow a grace period to liquidate existing stock or transition to alternate formulations, these notifications do not mention any sell-through or transition window. This makes immediate compliance review critical. Regulatory Process Timeline (For Context) Understanding how this ban evolved can help businesses anticipate future FDC reviews: 2021:  Expert Committee examines each FDC and finds them "irrational." Post-2021:  DTAB reviews the Expert Committee's findings and agrees in principle. DTAB Sub-Committee formed:  tasked with detailed examination of all irrational FDCs. Public notices issued:  Manufacturers and stakeholders allowed to submit precise data defending the combination. 28th December 2024:  Sub-Committee submits its final report recommending prohibition. DTAB agrees with the Sub-Committee's recommendation. 11th June 2026:  Central Government issues the final prohibition notifications under Section 26A. This roughly five-year process shows that FDC reviews in India move through multiple layers of expert scrutiny before a ban is finalised, which also means businesses holding FDC licences should track ongoing DTAB reviews proactively rather than waiting for a final notification. Why Was This Implemented? The government's stated objective across all 16 notifications is consistent: protecting public health by removing drug combinations that carry risk without adequate therapeutic justification, especially where safer alternatives already exist. Key objectives include: Patient safety:  removing combinations where the risk-benefit balance does not favour the patient. Scientific rigour in drug approval:  ensuring that combination drugs are backed by real clinical evidence, not just commercial convenience. Rational use of medicines:  aligning with India's broader effort (going back to earlier FDC bans in 2016 and subsequent years) to clean up the market of combinations that lack a sound pharmacological basis. Alignment with standard treatment guidelines:  as seen with the Gliclazide + Chromium Picolinate case, where the combination did not match national or international treatment protocols. Preventing irrational polypharmacy:  several banned combinations added ingredients (such as enzymes or vitamins) to established drugs without clear added benefit, increasing exposure to side effects unnecessarily. Impact on Businesses Manufacturers:  Manufacturers currently producing any of the 16 listed FDCs must immediately halt production. Continuing to manufacture a prohibited drug can expose the company to penal action under the Drugs and Cosmetics Act, including seizure of stock and cancellation of related manufacturing licences. Importers:  If any of these combinations are imported into India in finished or bulk form, import of the prohibited combinations must stop. Import licences tied specifically to these formulations will need to be reviewed and, where applicable, surrendered or amended. Exporters:  The notices specifically limit manufacture, sale, and distribution for human consumption in that country. Firms that export such combinations need to carefully consider whether an export manufacturing operation is feasible, since the export business remains subject to India's regulations and manufacturing laws. Brand Owners and Marketing Companies:  Brand owners who outsource manufacturing (loan licensing/third-party manufacturing arrangements) are equally responsible for compliance. Marketing and promotional activity for these brands must stop immediately, including trade communication, MR (medical representative) detailing, and e-pharmacy listings. MSMEs and Startups:  Smaller pharmaceutical manufacturers, often reliant on a narrower product portfolio, may feel a sharper financial impact from a sudden ban. MSMEs should prioritise a rapid compliance review to avoid inventory write-offs that could lead to legal exposure. Large Enterprises:  Larger pharma companies with wide product portfolios should still treat this as serious regulatory non-compliance; even one SKU can trigger scrutiny of the entire manufacturing licence and facility. Traders, Distributors, and Retailers:  Anyone holding existing stock of these 16 combinations from stockists to retail pharmacies should stop further sale and consult with their supplier or a regulatory expert on the appropriate way to handle existing inventory. Service Providers (Formulation Developers, CROs, CDMOs):  Contract development and manufacturing organisations (CDMOs) and formulation R&D teams working on any of these combinations, or structurally similar combinations, should reassess ongoing projects in light of the reasoning given in these notifications, since similar combinations may face similar scrutiny in future DTAB reviews. How will Businesses achieve Compliance? The following is a compliance roadmap for businesses impacted by the notification: Step 1: Verification of Impact Verify whether you fall within the scope of the notification by cross-verifying your product range, active pharmaceutical ingredients used, and drug manufacturing licence (Form 25/28). Variations in the ratio or additional inclusion of ingredients may still place your business within the scope of this notification. Step 2: Immediate Suspension of Production, Sales and Distribution Since the ban is immediate, businesses cannot plan for a gradual closure. The manufacture, marketing material, and distribution must be stopped immediately. Step 3: Modification of your Manufacturing Licences Your manufacturing licence (form 25/28) might require modification, as the banned combination must be removed from the approved products under your licence. Step 4: Disposal of existing Stock It cannot be assumed that stock manufactured earlier is exempt from this ban. Seek advice from the State Drug Control Authority regarding proper disposal or recall procedure. Step 5: Communication to Distribution Network Send a communication about the ban to your distribution channel so the product is removed from sales channels. Step 6: Review of Research Pipeline If your research pipeline includes other combinations that have been banned, reconsider the scientific justification based on the DTAB findings before progressing further. Step 7: Documentation Document all compliance measures in case any scrutiny happens in the future. Common Compliance Mistakes to Avoid Assuming a "grace period" exists when the notification says "immediate effect." Continuing to sell existing inventory without checking with the licensing authority. Overlooking loan-licensing or third-party manufacturing arrangements when assessing exposure. Failing to update marketing and e-commerce/e-pharmacy listings promptly. Not documenting the compliance actions taken, which can matter significantly during inspections. If you're unsure whether your product formulation matches a banned combination exactly (for example, a similar but not identical ratio), don't self-assess. A regulatory consultant can help you interpret the notification in the context of your specific product dossier and avoid both over-compliance (unnecessarily halting a legal product) and under-compliance (continuing to market an illegal one). Benefits for Businesses That Get Compliance Right While a ban is disruptive, businesses that respond to it correctly and quickly stand to gain in several ways: Avoiding penalties and legal action under the Drugs and Cosmetics Act. Protecting manufacturing licences from suspension or cancellation risk tied to a single non-compliant product. Maintaining market and distributor trust, since a swift, professional response signals regulatory maturity. Freeing up R&D and manufacturing capacity to reformulate or pivot to compliant, evidence-backed alternatives. Reducing future regulatory risk by using this as an opportunity to review the rest of the product portfolio for similar irrational combinations. Smoother business continuity by acting early rather than waiting for a regulatory notice or inspection. Right Decision or Additional Burden? It's fair to look at this from both sides. From a public health standpoint, the ban is a reasonable and evidence-based decision. Each of the 16 combinations underwent a multi-year review, an Expert Committee assessment, a DTAB evaluation, a dedicated Sub-Committee review, and an opportunity for manufacturers to submit data before the final prohibition. That is a considerably more thorough process than an abrupt regulatory decision. As far as the business implications of the notification go, the lack of any phase-in period to ease the compliance process can pose practical problems: from excess stock to the need for immediate licence changes, all of which pose real obstacles. The balanced perspective: regarding the regulatory intent behind the notification itself, it is clearly a good move to eliminate drug combinations lacking scientific evidence. However, the time frame set by the regulators poses a challenge for those businesses that operated within legal boundaries until the announcement was made. Business Opportunities Created A regulatory disruption like this also opens doors: Reformulation opportunities- Companies can develop scientifically justified alternatives to replace the banned combinations, potentially capturing market share vacated by the ban. Consulting demand- Pharma companies across the country will need regulatory support to interpret and act on this notification, creating opportunities for compliance consultants and legal advisors. Portfolio review as a competitive edge- Companies that proactively audit their full portfolio against DTAB's ongoing "irrational FDC" review process can position themselves ahead of future bans. Trust-building with regulators- Businesses that respond transparently and promptly to this notification build long-term credibility with licensing authorities, which can smooth future approvals. Export and manufacturing realignment- Companies can use this as a trigger to review and modernise their broader manufacturing and product strategy. Why Choose Corpseed? Navigating a sudden regulatory prohibition like this is not something to handle informally. Corpseed works with pharmaceutical manufacturers, importers, and distributors across India on: End-to-end regulatory compliance support for drug licensing under the Drugs and Cosmetics Act, 1940 Manufacturing licence review, amendment, and renewal assistance Documentation support for stock recall, licence surrender, or product discontinuation Guidance on reformulation and fresh product approval pathways. Liaison support with State Drug Control Authorities and the Central Drugs Standard Control Organisation (CDSCO). Application filing for new drug approvals and licence modifications. Pan-India support for businesses operating across multiple states with different licensing authorities. Dedicated regulatory experts who track ongoing DTAB reviews so you're not caught off guard by future FDC prohibitions A transparent, structured process with clear timelines, so you know exactly where your compliance stands at every stage. Whether you need to urgently amend a manufacturing licence, manage existing stock of a banned FDC, or explore compliant reformulation options, Corpseed's regulatory team can guide you through the process without unnecessary delays. Corpseed's Core Message Regulatory notifications like this one don't leave room for a "wait and watch" approach. The prohibition is already in effect, and the risk of continuing to manufacture, sell, or distribute any of these 16 combinations grows with every day of inaction. If your business is affected even partially, even though a third-party manufacturing arrangement is the smartest move, it is to get a clear, expert read on your exposure before it becomes a compliance issue. Delayed action on drug prohibitions can lead to stock seizures, licence suspension, and reputational damage that takes far longer to repair than the compliance process itself. Corpseed's regulatory consultants can help you assess your exposure, manage the transition, and get your documentation in order so you can focus on running your business. At the same time, the compliance side is handled by people who track these notifications for a living. Talk to a Corpseed regulatory expert today to review your product portfolio against this notification and stay ahead of future FDC reviews.

Department: CDSCOAuthority: Ministry of Health & Family Welfare

🏷️04-08-2026

Subject

What Will Be the Impact of Adding High Alcohol Oral Formulations to Schedule H1?

Summary: The Ministry of Health and Family Welfare has released a new rule called the Drugs (Tenth Amendment) Rules, 2026. According to this regulation, all those liquid drugs that are highly alcoholic in nature have been put in Schedule H1. After doing this, the said drugs cannot be purchased without a prescription from a physician, and pharmacists will maintain a record of each sale made. What Are High-Alcohol Oral Formulations Under the New Rule? The 2026 amendment describes a clear group of medicines that now fall under stricter rules. A medicine belongs to this group if it meets all three conditions below: It is taken by mouth (an oral formulation). It contains more than 12% alcohol by volume (ethyl alcohol). It is sold in a bottle or pack larger than 30 millilitres. Common examples of such products include: Cough syrups with a high amount of alcohol. Liquid tonics that use alcohol to dissolve their ingredients. Large bottles of liquid medicine with a noticeable alcohol content. From now on, these products are treated the same way as other controlled prescription medicines listed under Schedule H1. What Has Changed in the Drugs Rules, 1945? The two important changes to the Drugs Rules, 1945 are: 1. Change to Schedule K (Exemptions) Schedule K is a list of medicines and situations that are excused from following the full Drugs Act and Rules. Serial number 10 of this list, under the heading "Extent and Conditions of Exemptions," has been edited. After the words "Act and rules thereunder," new wording has been added: "Except for all oral formulations containing more than 12% alcohol v/v (Ethyl Alcohol) packed and sold in packings or bottles of more than 30 milliliters." What this means: High-alcohol liquid medicines sold in bottles larger than 30 ml no longer get the exemption under Schedule K serial 10. Full compliance with the Act and Rules becomes compulsory. 2. Addition to Schedule H1 (Controlled Medicines List) Schedule H1 is the list of medicines that need extra care because of their risk of misuse. A new line has been added right after entry "51. Pregabalin": "52. All oral formulations containing more than 12% alcohol v/v (Ethyl Alcohol) are packed and sold in packings or bottles of more than 30 milliliters." What this means: These medicines now count as Schedule H1 items, which brings three main results: Sale is allowed only with a valid prescription. Pharmacies must maintain extra records of each sale. Sale over the counter, without a prescription, is no longer permitted. Implementation Date and Compliance Timeline Firstly, in this rule itself, there is a mention that: These rules can be termed the Drugs (Tenth Amendment) Rules, 2026. These will come into force six months from the date of their publication in the official gazette. Since the publication date is 10 July 2026, the rule is set to take effect around 10 January 2027. This gives businesses roughly six months to complete several tasks: Identify which products are affected. Update product labels and packaging details. Revise sales and distribution procedures. Train staff on how to handle Schedule H1 products correctly. Why Did the Ministry of Health and Family Welfare Introduce This Rule? The notification provides an overview of the steps taken before finalising the rule: The draft of the rule was published on 16 October 2025. The public had 30 days to object or suggest any changes. Drafts of the rule were published on 18 October 2025, but no objections or suggestions were received from the public. The Central Government adopted the rule after consulting with the Drugs Technical Advisory Board (DTAB). The main reasons behind this decision include: 1. Preventing Misuse High-alcohol liquid medicines can sometimes be misused as a substitute for alcoholic drinks. Placing them under Schedule H1 ensures a doctor stays involved and misuse is kept in check. 2. Protecting Public Health Large bottles with 12% or more alcohol content may cause intoxication or even damage to health when consumed inappropriately. 3. Removing Confusion Taking these products out of the Schedule K exemption list and clearly adding them to Schedule H1 removes any doubt about how they should be classified. 4. Matching Existing Safety Rules Schedule H1 also regulates medicinal drugs that have an abuse potential. Introducing high-alcohol formulations will only make it easy for these products to align with an existing regulation for this purpose. Generally, the intention is to regulate dangerous products and not promote the consumption of alcohol. Impact on Businesses in India Affected Stakeholders •    Manufacturer of oral liquid medicines containing more than 12% ethanol. •    Contract manufacturer of high-alcohol formulations. •    Distributors and wholesalers handle these liquid medicines. •    Retail and hospital pharmacies that stock such products. Compliance Requirements For Manufacturers Review the full product list to find:  Oral formulations containing more than 12% ethanol. Pack sizes larger than 30 ml. Reclassify the affected products as Schedule H1, which includes:  Updating labels and pack declarations. Adjusting marketing and distribution practices. Consider available options, such as:  Lowering the alcohol content to 12% or below. Reducing the pack size to 30 ml or less. Discontinuing products where the cost of compliance outweighs the business return. For Distributors and Wholesalers Keep a clear list of all Schedule H1 products handled. Supply these products only to properly licensed pharmacies. Update documentation practices to track high-alcohol Schedule H1 items. For Retail Pharmacies Consider all these products as Schedule H1 medicines. Sell these products on prescription only. Maintain proper registers and records regarding Schedule H1 products. Is This Rule a Right Decision or an Extra Burden? From a Public Health and Regulatory Perspective This step appears reasonable and necessary for a few reasons: High-alcohol formulations carry a real risk of misuse. Moving them into Schedule H1 places them under closer medical supervision. The rule was finalised only after consultation with DTAB, and the public raised no objections. It does not create unfairness for pharma companies or consumers: Consumers are not being pushed toward more alcohol access is being managed more carefully. Businesses that adapt responsibly can strengthen their reputation for trustworthiness. Business Burden There is, admittedly, some extra work involved: More record-keeping is required. Sales may dip for products that were previously easier to buy. Some products may need reformulation or a change in pack size. That said, this burden is: Reasonable when measured against the risk involved. Manageable with proper planning. An opportunity for companies to show leadership in following regulations. Consumer Safety, Quality, and Long-Term Satisfaction Quality and Safety The Schedule H1 will offer many advantages, such as: Greater supervision of the quality of manufacture and distribution. Improved monitoring of adverse effects and misuse patterns. Assurance that high-risk medicines are handled properly within the medical system. Consumer Satisfaction In the short term: Some inconvenience may arise due to the prescription requirement. In the long term: Safety outcomes are likely to improve. Harm linked to misuse is likely to decrease. Confidence grows that medicines are used correctly rather than as a substitute for alcohol. Impact on the Indian Economy and International Players Indian Economy The overall effect on the economy is modest but positive: A slight shift is expected in how controlled formulations are sold. Manufacturers are encouraged to reformulate and create safer products. Reduced misuse is likely to ease pressure on the healthcare system over time. Foreign and Multinational Pharma International companies will need to adjust their Indian product lines by: Reformulating products where needed. Adjusting pack sizes. Updating labelling and compliance processes. Clear rules like this one make the Indian market more predictable and reduce regulatory uncertainty for foreign players. Opportunities for Related Businesses Pharma Manufacturers Reformulation and Innovation  Development of low-alcohol or alcohol-free alternatives. Introduction of smaller pack sizes where clinically suitable. Portfolio Rationalisation  Phasing out high-risk products that are no longer commercially viable. Greater focus on safer, compliant products. Distributors and Pharmacies Building strong systems to manage controlled drugs. Using digital registers and standard procedures for Schedule H1 compliance. Turning compliance into a way of earning trust with hospitals and doctors. Health-Tech and Software Providers Designing pharmacy software that: Flags Schedule H1 products automatically. Requires prescription details before a sale is completed. Maintains the statutory logs and reports required by law. Corpseed's Business Opportunities Under the New Rule Corpseed is well placed to help businesses adjust to and benefit from this new classification: 1. Product Portfolio Compliance Audit Reviewing client product lists to identify formulations with more than 12% ethanol in packs larger than 30 ml. Providing a clear mapping of products against the new regulatory requirements. 2. Reformulation and Pack-Size Advisory In support of the decision-making process related to lowering alcohol levels, altering packaging size, and withdrawing specific products depending on risk and reward. 3. Labelling and Documentation Compliance Ensuring correct Schedule H1 markings, updated labels and packaging artwork, and full alignment with the Drugs Rules, 1945. 4. Pharmacy and Distribution Compliance Programs Provision of accurate Schedule H1 labelling and packaging artwork in full compliance with the Drugs Rules, 1945. 5. Training Modules for Sales and Pharmacy Staff Creating simple training material covering topics such as "What is Schedule H1?" and "How to handle high-alcohol formulations safely." 6. International Client Support Advice to multinational pharma companies regarding new Indian regulations on product modification and other issues related to compliance and the regulatory process. 7. Ongoing Regulatory Monitoring Service Tracking future changes to Schedules K and H1 and alerting clients early to any new controlled categories. By positioning itself as a specialist in pharma and healthcare compliance, Corpseed can turn this rule into a long-term line of advisory and implementation work.

Department: CDSCOAuthority: Ministry of Health & Family Welfare

🏷️20-07-2026

Subject

Government Proposes Amendments to Medical Devices Rules, 2017 to Speed Up Licensing

Summary: In June 2026, the government proposed a change to the Medical Devices Rules, 2017. The main goal is to make the process of getting a medical device license in India faster and easier. At the same time, the rules still keep safety and quality checks in place. This change helps companies that need a medical device manufacturing license or a medical device import license because it shortens the waiting time for approval. But it also means companies must keep better records and watch their products more closely after they are sold, which is often called post-market surveillance. The exact wording of the new rule is not public yet. So this article explains what usually happens when governments make medical device registration and licensing faster, and how such changes affect businesses across the healthcare sector. Big-Picture Impact on Businesses in India Faster and clearer licensing under the Medical Devices Rules usually changes business in four big ways. Companies applying for a CDSCO medical device license or planning medical device registration in India should watch each of these closely. Impact Area What It Means for Businesses Reduced time-to-market Shorter review times mean companies get their medical device license sooner. Devices reach hospitals and clinics faster. New companies making diagnostic tools, wearables, and home-care devices benefit the most, since delays can hurt small businesses badly and raise the cost of a slow medical device manufacturing license process. More predictable process Rules usually explain clearly what forms are needed, what data must be shown, and how devices are classified (Class A to D). This helps businesses plan a clear timeline for medical device registration and product launch. Higher expectations for records Faster approval usually comes with stricter checks before submission and standard templates. Companies with strong quality management systems find it easier to follow the rules. Companies with messy paperwork struggle more with medical device compliance. Shift to ongoing checks Instead of doing all checks before giving a license, the government checks products more after they are sold. Businesses must keep watching their products, report problems, and fix issues quickly to keep their medical device license valid. Overall, companies that care about quality gain the most. Companies that relied on slow, unclear rules to hide weak products lose out. Why the Government Is Bringing This Policy Now Several reasons are pushing the government to speed up medical device licensing in India. Reason Explanation Self-reliance in healthcare India wants to make more medical devices at home, from syringes to imaging machines, so it depends less on imports. A faster medical device manufacturing license process supports this goal directly. Lessons from COVID-19 The pandemic showed that slow approval for ventilators, oxygen machines, and test kits can put lives at risk. Long queues for a medical device license are a health problem, not just a business problem. Global competition Indian med-tech companies compete with companies worldwide. They need approval times similar to those in other big markets, or they lose investment and partnerships to countries with faster medical device registration systems. Modern regulation The government is moving medical devices away from old drug-style rules and toward rules based on risk level. Faster licensing is part of this update, alongside stronger post-market checks. This policy is meant to support new ideas and more manufacturing, not to lower safety standards. It moves effort away from slow paperwork and toward smarter, risk-based checking. Who Gets Maximum Benefits? Group How the Change Helps Indian device makers and start-ups Companies making diagnostic tools, surgical tools, implants, disposable items, hospital furniture, home-care devices, and wearables benefit most from shorter approval times for a medical device manufacturing license. Start-ups can also show investors that approval is faster, which helps them raise money. Importers and distributors Businesses bringing in advanced imaging machines, robotic surgery tools, and specialized supplies from countries like the US, EU, and Japan get quicker medical device import license registration and renewal. Hospitals and diagnostic chains Faster licensing gives hospitals more choice of equipment, often at better prices, since more companies can compete. It also helps hospitals offer new types of care, like day surgery and home monitoring. Patients and payers More competition among device makers usually leads to better quality at lower prices, especially for everyday items like syringes and monitors. Regulatory consultants and compliance firms Firms offering medical device regulatory consulting, dossier preparation, and quality system support see more demand as businesses rush to meet new, faster timelines. Who May Be Negatively Impacted or Feel "Losses"? Group Why They May Struggle Companies relying on unclear rules Businesses that used confusing classification or weak paperwork to get by will find it harder to hide problems, since faster screening finds gaps quickly during the medical device registration process. Small importers without strong teams Traders bringing in small amounts of niche devices without a compliance team may struggle with the stricter paperwork and digital filing needed for a medical device import license. Companies that ignore post-sale checks Businesses that do not track complaints, device failures, or safety issues after selling their products will face more trouble, fines, and damage to their reputation. In short, honest, quality-focused companies come out stronger. Companies that depend on slow, unclear systems to avoid scrutiny face more risk and cost. What Was the Requirement for This Policy The rule change is meant to fix several long-standing problems tied to the medical device license in India's processes. Problem Explanation Licensing delays Businesses have long complained that getting a medical device license, especially for higher-risk devices (Classes C and D), can take many months, hurting their plans and delaying medical device registration in India. Confusing process Overlap and unclear roles between the Central Licensing Authority and State Licensing Authorities caused delays and confusion for applicants. Unclear classification Confusion around how devices are placed into Class A, B, C, or D slowed down approvals and caused disagreements between businesses and regulators. Global alignment India is trying to match international standards used by groups like IMDRF, EU MDR, and the US FDA, making the medical device registration system more attractive to global companies. Digital push Moving to online systems, trackable timelines, and standard forms fits with the government's larger goal of making business easier for anyone seeking a medical device license. Impact on India's Economy Positive Impacts Area Expected Benefit Manufacturing and exports Shorter approval times and clearer rules attract more investment into Indian device-making and design. More devices will be built and sold abroad, boosting demand for medical device manufacturing license support. Less dependence on imports A better system encourages local production of items that used to be imported, such as disposables, basic monitors, and diagnostic kits, reducing reliance on a medical device import license pathway. Healthcare quality Better and more available devices in hospitals can improve patient care and make the healthcare system work better overall. New ideas and research Universities and research labs find it easier to turn new inventions into real products, strengthening India's device-making community and creating new demand for medical device registration support. Risks and Limits If licensing becomes too fast without enough checking after sale, unsafe or poorly tested devices could reach the market. Regulators need enough trained staff and good systems to handle the extra workload. Still, the overall economic effect is expected to be positive if the government keeps up its ability to monitor the market and support businesses seeking a medical device license. Is This the Right Decision or an Added Burden? Reasons It Is Largely the Right Decision The change brings India closer to global best practice, using rules based on risk level, clear timelines, and open processes instead of slow, unclear steps. It supports new ideas, investment, and better access to healthcare, especially important in a country that needs affordable medical devices on a large scale. It does not weaken safety; it shifts focus from bureaucratic delay to stronger paperwork and better checking after sale for every medical device license holder. Where Difficulties May Arise Who What They Must Do Businesses Improve internal record-keeping and quality systems, keep track of product safety consistently, and adjust quickly to new forms, timelines, and online systems for medical device registration. Regulators Train staff on new processes and digital tools, and manage a bigger number of applications as approval becomes faster for a medical device license. Conditions for Business Clear guidance, fixed timelines, and risk-based steps make planning and investing easier. Faster licensing lowers uncertainty, making India more attractive for global medical-device partnerships and easier for local firms seeking a medical-device manufacturing license. Transparency Rule changes like this usually spell out clearly what type of application is needed, what each device class requires, and expected timelines, along with how to escalate delays. When paired with online tracking systems, businesses can always see where their medical device registration application stands. Safety and Environment Better classification lets regulators focus more attention on high-risk devices, such as Class C and D items and critical implants, while making the process simpler for low-risk items. Stronger checks after sale and quicker safety corrective actions should improve patient safety overall. Devices that affect the environment, such as single-use plastics or electronic waste, are usually handled by separate environmental rules rather than by this licensing change itself. Compliance and What Businesses Need to Do Although the exact wording of the new rule is not yet public, businesses should prepare to focus on the following steps to secure a smooth medical device license approval. Requirement Details Correct device classification Placing devices in the right class (A to D) and using the correct medical device registration path. Complete documentation Preparing a technical file, clinical or performance evaluation data, risk management and biocompatibility data, and quality system certification such as ISO 13485 certification. Digital filing Submitting and tracking applications through government online portals, keeping timelines in mind. Post-sale monitoring Setting up systems for handling complaints, reporting safety problems, and taking quick corrective action when needed to keep a medical device license active. Companies without an internal regulatory or quality team will likely need outside help from a medical device regulatory consultant to meet these requirements. Opportunities for Corpseed This reform opens strong opportunities for Corpseed to grow its medical device regulatory consulting services and support businesses seeking a medical device license or medical device registration in India. Service Area What It Covers Licensing fast-track consulting Full support for Medical Device Rules, 2017 licensing, including device classification, document preparation, and communication with regulators for a medical device manufacturing license or medical device import license. Regulatory health-check Reviewing existing licenses and paperwork against new requirements, spotting gaps, and creating upgrade plans for current medical device license holders. Start-up medical device packages Tailored support for early-stage companies, including choosing the right pathway, guidance on designing for compliance, and planning for time-to-market. Post-market surveillance and quality system services Building complaint-handling systems, safety corrective action workflows, and full quality system implementation and audits, including ISO 13485 certification support. Training and capacity building Workshops for hospitals, diagnostic chains, manufacturers, and importers on new rules, safety duties, and digital filing for medical device registration. Support for international manufacturers Helping foreign device companies enter the Indian market, including local representation, license applications, and meeting India's quality and safety requirements for a medical device import license.

Department: CDSCOAuthority: Government of India

🏷️06-07-2026